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Abstract 
 
BACKGROUND. With 1.3 million new breast cancer cases reported every year and 
improved survival, it is important to develop interventions to maintain health related 
quality of life (HRQOL) during and after cancer treatment. Aerobic and strength training 
is an intervention that can enhance HRQOL and physical components during 
treatment.  
OBJECTIVES. To examine the effect of 12 weeks of supervised exercise in physical 
capacity measurement and HRQOL in breast cancer patients during treatment. 
METHODS. Breast cancer patients were allocated into an exercise intervention 
program (EI, n=40) and to a control group (CG, n= 8) that received standard care. The 
intervention comprised cardiovascular training at 70-85% of VO2max in cycle ergometer, 
resistance training and specific rehabilitation arm exercises. Patients were trained 
during 60 minutes, two times per week, during 12 weeks, with progression in time and 
intensity during the intervention period, with the main goal to achieve, at week 12, thirty 
minutes at 85%VO2max. Physical capacity and health related quality of life EORTC 
QLQ-C30 were assessed pre and post intervention. General linear model for repeated 
measures was used to compare (baseline and 12-week follow-up) with group 
assignment and time x group interaction included as fixed effects (p.05 for 
significance). 
RESULTS. Highly significant increases were achieved with an increase of 17.0% vs. 
7.7% in VO2max, and 46,6% vs. 4.9% in power output, respectively, in the intervention 
group compared to the control group (p.05). Gains in strength occurred only in the 
intervention group with and increase in leg extension by 13.4% (p.05). Intervention 
and control groups improved global health status (10.2 vs. 9.3 points) but emotional 
status (16.6 vs. 11.0 points) and role function (14.9 vs. -0.1 points) were significantly 
higher in the intervention group (p.05). The fatigue decreased by 16.4 points in the 
intervention group compared with only 2.7 points in the control group (p<.001). A 
significant decrease in pain was obtained for the intervention group with a reduction by 
20.4 points vs. 2.6 points for the control group (p<.001). 
CONCLUSIONS. A supervised and individualized prescriptive exercise program, 
results in an improvement in functional ability and HRQOL functions in women with 
breast cancer. 
 
KEY WORDS: Quality of Life, Exercise, Breast Cancer, Fatigue.
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Resumo 
INTRODUÇÃO. Com 1.3 milhões de novos casos de cancro todos os anos e com o 
aumento da taxa de sobrevivência, é importante desenvolver intervenções 
relacionadas com a qualidade de vida (QOL) durante e depois do tratamento do 
cancro. O exercício físico pode ser uma estratégia não farmacológica para melhorar a 
QOL e a capacidade física durante o tratamento da doença.  
OBJETIVOS. Avaliar o efeito de um programa de exercício físico supervisionado 
durante 12 semanas nas alterações físicas, funcionais e a QOL, durante o tratamento, 
em mulheres com cancro da mama. 
MÉTODOS. As mulheres com cancro da mama foram incluídas em dois grupos 
distintos, sendo que 40 participaram num programa de exercício físico (EF, n=40), 
enquanto que as restantes integraram o grupo de controlo (GC, n=8). O programa de 
exercício físico consitiu em treino cardiovascular no ciclo-ergómetro a 70-85% VO2max, 
treino de resistência de força com bandas terapêuticas e exercícios específicos de 
reabilitação para os membros superiores. O programa de exercício físico teve a 
duração de 60 minutos, duas vezes por semana durante 12 semanas. Durante o 
período de aplicação do programa de exercício físico houve uma progressão no tempo 
e intensidade com o objetivo de realizar na 12ª semana 30 minutos a 85% VO2max. A 
capacidade física e a QOL (EORTC QLQ-C30) foram avaliadas antes e depois do 
programa de intervenção. Para comparar o efeito do programa de exercício físico 
antes e após a intervenção utilizou-se a Anova de medidas repetidas com a análise da 
interação tempo x grupo (nível de significância p.05). 
RESULTADOS. Verificaram-se aumentos significativos de 17.0% vs 7.7% no VO2max e 
46,6% vs 4.9% na potência ao VO2max, respectivamente no EF comparado com GC 
(p.05). O aumento da força na leg extension ocorreu apenas no EF 13.4% (p.05). 
Ambos os grupos aumentaram a qualidade de vida geral (10.2 vs 9.3) mas a função 
emocional (16.6 vs 11.0) e role função (14.9 vs -0.1) foram significativamente mais 
altos no grupo EF (p.05). A fadiga diminuiu cerca de 16.4 pontos no grupo EF 
comparativamente com 2.7 pontos no GC (p<.001). Foi demonstrado um decréscimo 
significativo da dor apresentado apenas pelo grupo de intervenção com uma redução 
de 20.4 vs 2.6 pontos para o grupo de controlo (p<.001).  
CONCLUSÕES. Um programa de exercício físico supervisionado, individualizado e 
prescritivo durante 12 semanas induziu numa melhoria significativa das capacidades 
funcionais e  QOL em mulheres com cancro da mama.  
PALAVRAS-CHAVE – Qualidade de vida, Exercício, Cancro da Mama, Fadiga. 
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In the western world, cardiovascular and oncologic diseases are the main 
causes of premature death (Pedersen & Saltin, 2006). Cancer is the leading 
cause of death in economically developed countries and the second leading 
cause of death in developing countries. The burden of cancer is increasing in 
economically developing countries as a result population aging and growth as 
well as, increasingly, an adoption of cancer-associated lifestyle choices 
including smoking, physical inactivity, and fast food (Jemal et al., 2011). Breast 
cancer in female and lung cancer in males are the most frequently diagnosed 
cancers and the leading cause of cancer death for each sex in both 
economically developed and developing countries except lung cancer is 
preceded by prostate cancer as the most frequent cancer among males in 
economically developed countries (Jemal et al., 2011). 
Worldwide, 1.3 milion new breast cancer cases were reported every year 
accounting for 23% of the total new cases and 14% (458.000) of the total 
cancer deaths in 2008 (Jemal et al., 2011). More recent studies in the United 
States estimate that the 5-year survival rate for all cancers is roughly 62% and 
represents an approximate total of 9 million cancer survivors. The annual 
percentage change in the incidence of invasive breast cancers decreased 
modestly among older women but increased among younger (<40 years) and it 
has been reported that approximately 25% of breast cancers occur in women 
less than 50 years of age (e.g. premenopausal) in Europe and in US (Brinton et 
al., 2008). Early detection and advanced treatment option have led to a steady 
improvement in 5-year relative survival rate in developed countries where the 5-
year relative survival rate is currently 87% (Eheman et al., 2012). Data from 
2003 show that 5-year relative survival exceeded 90% for patients with breast 
cancer and reached levels of about two thirds for patients with colorectal cancer 
and kidney cancer and patients with non-Hodgkin's lymphoma (Brenner et al., 
2007). 
This trend has resulted in a growing population of breast cancer survivors who 
are potentially faced with a number of long-term side effects of cancer and its 
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treatment (Campbell et al., 2011). Some of these include decrease aerobic 
capacity and strength, weight gain, fatigue and reduced quality of life.  
 
Treatment is focused on curing the disease and preventing relapse due to 
metastic disease (Hoving et al., 2009). This fact accentuates the importance of 
investigation regarding the development of strategies to improve patients’ 
quality of life, reduce the recurrence risk, the probability of contracting other 
diseases and prolonging the population’s survival (Courneya, 2003). 
The quality of life in oncological patients is often affected by the fatigue that they 
feel. In fact, approximately 70% of the cancerous population reports sensations 
of fatigue and asthenia during radiotherapy, chemotherapy or after surgery. 
Furthermore, approximately 30% of the population that survives cancer 
continues to manifest signs of persistent fatigue (Dimeo, 2001). Therefore, in all 
the types of cancer, the cancer related fatigue (CRF) severely influences 
several components of the quality of life since in aggravating symptoms like 
pain, nausea and dyspnoea, it causes physical, economic and social 
consequences that are devastating to the patients (Winningham, 2001). Cancer 
related fatigue (CRF) as a profound, negative impact on daily activities, social 
activities and overall quality of life (Cella et al., 2002).  
Devoogdt et al. (2010) studied the evolution of the total physical activity levels 
occupational, sport and household activity on breast cancer patients. Physical 
activity levels are still significantly lower 12 months after treatment for breast 
cancer than at the pre-operative level. A greater decrease in occupational 
activities was associated with having a spouse, lymph node stage pN2 or pN3 
(versus stage pN0 or pN1) complete axilary dissection (versus sentinel node 
biopsy), more than 20 lymph nodes dissected (versus less than 10) or 
undergoing chemotherapy. Moreover, older patients and those smoking before 
surgery had a higher risk of having a decreased sport activity level 12 months 
after surgery. 
In this study, 1 year after the surgery breast cancer patients showed a 85% 
reduction from baseline in occupational activities (Devoogdt et al., 2010). 
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So, cancer patients, and in particular those at risk for a decreases physical 
activity level and affected by fatigue, should be identified, and encourage to 
increase their activities with supervised exercise programs. In fact, CRF and 
decreased physical activity may leed to difficulties in return to work.  
Being unable to return to work after cancer treatment, frequent or prolonged 
work absenteeism, or problems with work performance may impose a 
significant economic impact on the survivor and her family (Chirikos et al., 
2002). Furthermore,  it is stated that the longer people are absent from their 
jobs, the lower the likelihood is that they will ever return to work. Moreover, 
Whereas loss of occupational identity can be a source of significant anxiety and 
depression, continuing or returning to the workplace allows many patients to 
maintain a sense of normalcy or control (Peteet, 2000). Most of the 
interventions with patients receiving adjuvant treatment show some 
improvement on quality of life or an other physical and psychological outcomes, 
such CRF, but do not pay attention to the aspect of work which is considered to 
be an important contributor to quality of life (Hoving et al., 2009). Some studies 
investigated return to work following breast cancer surgery. In a systematic 
review, Hoving et al. (2009) concluded the lack of methodology sound 
intervention studies on breast cancer survivors with outcome return to work 
indicating that returning to work programs and vocational rehabilitation for 
breast cancer survivors should be further developed and evaluated. 
At 3 months pos-operative surgery, only 19% of patients working pre-
operatively has returned to work and after 12 months the proportion had 
increased to 60% with patients working in a part-time employment than before 
surgery (Devoogdt et al., 2010). In other study elaborated in Canada, showed at 
12 months, 88% of  the breast cancer patients had returned to work (Drolet et 
al., 2005). There is a high variability among studies about working rates after 
breast cancer surgery being a possible explanation the difference in health care 
systems between US, Canada and European countries. In US, after 3 months, 
60% of breast cancer patients were working but assistance with transportation, 
limitation in upper-body strength, and employment in jobs requiring physical 
activiy were needed (Satariano & DeLorenze, 1996).  
 18 
In light of this information, it is the general purpose of this study is analyse and 
describe the advantages of the individualized effect of training and exercise, 
with a clinic purpose, in the alteration of the aerobic/ muscular functions and 
quality of life outcomes in breast cancer patients during treatment. 
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2.1 Cancer Related Fatigue 
Every day people experience fatigue and this symptom is commonly associated 
with diseases such as depression, multiple sclerosis, arthritis and renal disease, 
as well as different medical and pharmacological treatments (Schwartz et al., 
2001). Patients treated for cancer disease experience a different and more 
disruptive fatigue. In fact, cancer related fatigue (CRF) is the most prevalent 
and disturbing side effect of treatment for the majority of cancer patients. CRF is 
described as being more intense and overwhelming than fatigue before 
treatment, and exercise is an intervention proposed to reduce fatigue (Adamsen 
et al., 2004; Dimeo et al., 1999; Lucia et al., 2003; Oldervoll et al., 2003; 
Watson & Mock, 2004). 
Cancer induces an abnormal inflammatory response with a high level of pro-
inflammatory cytokines that are responsible for the progression and clinical 
deterioration of the disease (Winkelman, 2004). Cancer treatment itself 
contributes to muscular atrophy, through the use of high doses of 
immunosuppressant drugs such as cyclosporine, cyclosfosfamide or 
glucocorticoids that increase the protein catabolism. The muscular atrophy is 
essentially the result of the production of tumour necrosis factor-alpha (TNFa) 
that accentuates the inflammatory response in the musculoskeletal structure 
(Winkelman, 2004). 
Most investigators consider that the origin of CRF is multifactor and not just a 
result of a single factor (Lucia et al., 2003; Ryan et al., 2007; Stasi et al., 2003; 
Watson & Mock, 2004); on top of that, the interaction between the various 
aetiological mechanisms is complex. In fact, fatigue represents just a part of the 
problem that is the physical incapacity experienced by cancer patients. Fatigue 
is usually defined as a sensation of lack of physical strength, weakness or loss 
of energy. However, fatigue becomes a pathological condition when it persists 
in ordinary daily activities, perseveres during a long period of time, does not 
improve with rest, or becomes severe enough so that it reduces daily physical 
activity (Dimeo, 2000). Although surviving cancer is a growing reality, medical 
intervention is almost always necessary.  
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2.1.1 Treatments and Toxicity 
The most common treatments for cancer are surgery, radiotherapy and 
chemotherapy. Despite these medical interventions, the patients’ quality of life 
may suffer consequences. Since in 60% of cases of cancer survivors surgery is 
used, depending on the location and the extent of the operation, a significant 
morbidity may occur (complications with wounds, infections, loss of function, 
diminished movement amplitude, diarrhoea, dyspnoea, pain, drowsiness and 
lymphatic oedema) (Courneya, 2003). 
Radiotherapy is used at a certain stage of the treatment in approximately 50% 
of cancer survivors. Generally, radiotherapy is administered in small fractions 
repeated over a period of 5 to 8 weeks to maximize the cellular death of the 
cancerous cells and minimize the damage to normal cells (Courneya, 2003). 
However, it can induce toxicity in normal cells and depends on the location of 
the radiation (pain, blistering, reduced elasticity, diminished movement 
amplitude, nausea, fatigue, pulmonary fibrosis, dry mouth, and 
cardiomyopathy). 
The tumour suppressor protein p-53 is required for most DNA-damage-induced 
apoptosis. Unfortunately, mutations in the p-53 gene are observed in upwards 
of 70% of human cancer cases, thus reducing the efficacy of some therapies 
(63-14). After surgery to remove a tumour (lumpectomy or mastectomy), high 
levels of ionizing radiation are used to destroy any remaining breast cancer 
cells in the breast, chest wall, or axillary area. Cell death from radiation therapy 
occurs primarily during mitosis, when extensive DNA damage makes 
duplication of the genome impossible (mitotic cell death). P-53 Dependent 
apoptosis occurs at the G1 checkpoint of the cell cycle and ensures that DNA 
carrying genomic defects is not replicated. However, in the absence of p53, or 
when p53 is not functional, the cells become insensitive to low doses of 
radiation. A high dose of radiation induces necrosis and cytoplasmic 
constituents being released into the surrounding tissue, which serves as potent 
inflammatory signals (Bower et al., 2009). Recent data suggest that the fatigue 
experienced with radiation therapy is associated with the activations of 
proinflammatory cytokines (Bower et al., 2009).  
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Systemic therapy is prescribed in several types of cancer. This treatment may 
be chemotherapy, hormone therapy and immunotherapy. Chemotherapy is 
administered intravenously or orally, in repeated cycles during 2-4 weeks from 3 
to 6 months. Chemotherapy may cause some adverse effects such as fatigue, 
anorexia, nausea, neutropenia, peripheral neuropathies, ataxia and cardio 
toxicity. Furthermore, approximately 55% of patients are submitted to adjuvant 
chemotherapy during the intervention. 
Chemotherapy drugs can disrupt the cell cycle at several critical steps and 
thereby induce apoptosis. Taxane drugs work to bind and stabilize cell 
microtubules to prevent them from separating chromosomes during cell division 
(anaphase of mitosis), thereby arresting cell cycle; doxorubicin (adriamycin) 
prevents DNA replication by inhibiting the enzymes, topoisomerases, that cut on 
strand of the DNA to unwind it during replication; and 5-fluorouracil (5FU, 
adrucil) inhibits thymidylate synthetase that functions to incorporate the thymine 
nucleotide into DNA during replication. Some of the more rapidly dividing 
normal, healthy cells are damaged (e.g. hair follicles, blood cells), subsequent 
mitosis from resident stem cells can soon replace those lost to chemotherapy or 
radiation (Clarkson & Kaufman, 2010). Over the past years, different studies 
have shown that fluorouracil, doxorubicin and cyclophosphamide (FAC) 
regimen as an adjuvant therapy for early stage of breast cancer is an effect 
treatment. Moreover, the doxetaxel, doxorubicin and cyclophosphamide 
regimen (TAC) has recently shown significant improvements in the rates of 
disease-free and overall survival even more than FAC (Lee et al., 2009). Some 
studies showed that TAC was more toxic than FAC with respect to neutropenic 
fever events and many extra hematological side effects such as asthenia, 
stomatitis, diarrhea and myalgia (Martin et al., 2005). Moreover, breast cancer 
patients who received TAC as treatment had less QOL scores, compared with 
FAC after the end of chemotherapy. Nevertheless, these differences gradually 
disappeared in different scales of QOL lasting for months after finishing 
chemotherapy (Bastani & Ahmad Kiadaliri, 2011). So, during follow-up period, 
patients in the TAC group experienced a higher improvement than FAC group. 
Hormone therapy is administered orally and can have several side effects such 
as weight gain, loss of muscular mass, accumulation of fat mass in the torso 
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and face, osteoporosis, fatigue and increased susceptibility to infections 
(Demark-Wahnefried et al., 2012). Lastly, immunotherapy is a recent form of 
treatment that maximizes the effect of other drugs as well as the defence 
mechanisms against cancerous cells. However, currently, in several clinical 
cases a combination of various types of treatment is being applied. In this 
situation, the timing and the treatment sequence depends on the staging and 
type of cancer. Consequently, it is possible that some cancer survivors may be 
treated on several occasions with different forms of treatment (Courneya, 2003). 
The supply of oxygen to the mitochondrion is a critical factor in the regulation of 
energy production. An adequate supply of energy to the cells requires the 
integrity of all the stages in the capture cascade, transport and use of oxygen. 
Anatomical and functional alterations due to the treatment of cancer can affect 
cells’ oxygen supply. On the other hand, the treatment itself, in inducing 
cardiovascular toxicity, can cause a dysfunction of the left ventricle (indicated by 
diminished systolic volume), ventricular contractility alterations and 
consequently diminished cardiac debt. Furthermore, pulmonary toxicity resulting 
from the treatment may cause a reduction of the lung’s full capacity, diminished 
vital capacity, a reduction of the inspiratory and diffusion capacities which, in its 
turn, compromise O2 and CO2 gas exchanges (Schneider et al., 2007). 
Moreover, diminished pulmonary volume due to illness (pulmonary metastases 
and pleural effusion) or as a sequel of the treatment (lobotomy, pulmonary 
fibrosis after radiotherapy) may alter the ventilation-perfusion ratio, causing 
difficulty to the saturation of haemoglobin (Lucia et al., 2003).  
Therefore, the treatment of cancer can reduce O2 transport capacity through the 
aerobic path by the different path of physiological mechanisms (Dimeo, 2000; 
Lucia et al., 2003). 
This toxicity is often observed in women with breast cancer during and after 
treatment. However, these negative effects can be attenuated through the 
intervention of an exercise programme. By means of an exercise intervention of 
3 weekly training sessions over a period of 6 months, between 45-75% HRmax, 
Schneider et al. (2007) observed, in breast cancer survivors, improved systolic 
arterial pressure (-2.6%), diastolic arterial pressure (-3.4%), and cardiac 
frequency at rest (-4.0%), while pulmonary capacity assessed by vital capacity 
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improved (+2.8%), as did maximum oxygen consumption (+15.1%). In the 
specific case of chemotherapy, the marrow may be affected, which 
consequently diminishes the production of red blood cells. Cardiotoxic cytostatic 
agents, such as anthracycline and cyclosfosfamide, can reduce blood flow to 
the musculo-skeleton (Dimeo, 2000).                                      
The loss of muscular function induced by a prolonged period of bed rest can 
result in a substantial loss of muscular mass, plasmatic volume and reduced 
cardiac debt that impairs energetic efficiency (Levine et al., 1997). This clinical 
status is very similar to being bedridden, since 6 weeks in this condition was 
enough to induce diminished left ventricular mass in 8.0+2.2% and is connected 
to reduced final diastolic volume on the second week in 14+1.7% (Perhonen et 
al., 2001). Furthermore, treatment with high doses of corticosteroids results in 
diminished muscular mass. Inducing immunosuppression using cyclosporine 
(CsA) may result in mitochondrial myopathy, loss of capillary density and, 
consequently, loss of physical capacity (Zbreski et al., 2006). CsA is an 
immunosuppressant commonly used in organ transplants. This drug acts as a 
cytosolic phosphatase protein inhibitor in T-Killer lymphocytes. In the Zbreski et 
al. (2006) study, the administration of CsA resulted in muscular atrophy, 
inducing a 22% decrease in fiber cross-sectional area. These last occurrences 
are clinically indistinguishable from alterations caused by detraining or by 
reducing physical activity. 
The majority of breast cancers are estrogen receptor-positive, although 
estrogen receptor negative disease is more frequent in premenopausal  (37%) 
than postmenopausal women (21%) (Anderson et al., 2002). Breast cancers 
that occur in younger women are of concern because these cancers are often 
hormone receptor negative (estrogen receptor ER- and progesterone receptor 
PR-), are high grade, and are diagnosed at advanced stages (Klauber-
DeMore, 2005). Current treatment guidelines recommend that premenopausal 
women with hormone receptor-negative disease receive adjuvant 
chemotherapy, and that those with hormone-positive disease receive adjuvant 
endocrine therapy (tamoxifen +- ovarian function suppression) with or without 
adjuvant chemotherapy based on the biology and extend of the primary tumor 
within the breast and regional lymph nodes (Burstein et al., 2010). Among the 
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adjuvant therapy options for premenopausal patients with breast cancer, both 
endocrine therapy (ovarian suppression or tamoxifen) and chemotherapy can 
result in substantial bone loss from suppression of estrogen levels (Headley et 
al., 1998; Nikander et al., 2012).  
Women who have premature menopause as a result of chemotherapy due to 
breast cancer are at an increased risk of bone loss and may be at risk for early 
development of osteoporosis (Headley et al., 1998). Moreover, women who 
became permanently amenorrheic as a result of chemotherapy had 14% lower 
bone mass density than women who maintained menses after chemotherapy 
(Headley et al., 1998). Rates of bone loss occurring with cancer therapy can be 
up to tenfold higher than normal (Guise, 2006).  
Nikander et al. (2012) examined the impact of aerobic exercise training 
(3x/week) in bone structural strength and observed a positive training effects on 
bone structural traits (1.2%), physical performance (~3-4%) and body 
composition (~1-3%) in breast cancer patients. However, resistance training is 
more effective in maintaining bone density (Schwartz et al., 2007). Knobf et al. 
(2008) conducted 12-24 week supervised weight-loaded aerobic intervention 
with women with breast cancer who were 3 year from completing breast cancer 
treatment. Bone remodeling was measured by serum biomarkers and no 
significant changes in serum osteocalcin, or lean muscle mass were observed. 
However, women at high risk for weight gain and bone loss maintained their 
weight and bone mass. A home-based strength training intervention, in 
postmenopausal breast cancer survivors with ostopenia or osteoporosis, 
resulted in improvements on bone mineral density with a significant increase in 
muscle strength for hip flexion, hip extension, and knee flexion, and BMD of the 
spine and hip (Waltman et al., 2003). A controlled pilot trial was carried out to 
assess the feasibility and efficacy of an aerobic exercise in enhancing physical 
performance of breast cancer patients after adjuvant treatments. Aerobic and 
step training during 12 weeks and the magnitude of the load during training 
sessions, which seemed to be sufficiently high to increase bone mass in 
different patients, suggest that this kind of vigorous training regimen is feasible 
among breast cancer survivors and could have a potential to prevent bone loss 
from the adjuvant treatments of breast cancer. To prevent bone loss, intense 
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aerobic exercise appeared to be well-tolerated and an effective training mode 
among breast cancer survivors who had recently completed heavy adjuvant 
treatments such as chemotherapy (Nikander et al., 2007).  
As cancer treatment regimens evolve, patients live longer but, sometimes, with 
the unwanted complication of anaemia. Anemia is a common haematologic 
manifestation in cancer and can increase the disease’s aggressiveness, causes 
fatigue and reduces quality of life (QOL) and can also limit the treatment (Straus 
et al., 2006). 
One of the many causes of CRF is anemia which comes with the disease and 
its treatment. Although it is not the only cause of CRF, anemia is the easiest to 
document using standard complete blood count haemoglobin (Hgb) levels for 
mild (10.00-11.99 g/dL), moderate (8.00-9.90 g/dL), and severe (<8.00 g/dL) 
anemia. These clinical definitions allow us to establish criterion of anemic 
cancer patients who can be tested for levels of self-reported fatigue and its 
impact on function (Cella et al., 2002).  
Moreover, it has been demonstrated that a state of anemia is an indicator of a 
disease’s independent prognosis (Ludwig & Strasser, 2001). It has also been 
demonstrated in cancer patients that a state of mild or moderate anemia (Hb 
values 10-12g/dL and 8-10g/dL, respectively) is significantly associated with a 
low survival rate (Ludwig & Strasser, 2001). In cancer patients, the incidence of 
chronic anemia depends on the type of malignancy, the staging and duration, 
and also type and intensity of treatment (Ludwig & Strasser, 2001).  
A multinational study, comprising Europe, carried out by the European Cancer 
Anaemia Survey (ECAS) documented the prevalence, incidence and severity of 
anemia in a numerous and representative sample of the European cancerous 
population (Ludwig et al., 2004). In this study it was demonstrated that anemia 
was more frequent in patients with gynaecologic cancers (81,4%), lung cancer 
(77,0%) and lymphoma/myeloma (72,9%). Some authors report that the 
prevalence of anemia is particularly high in patients with lung carcinoma (50%-
60% with Hb <11 g/dL) (Kosmidis & Krzakowski, 2005; Ludwig et al., 2004), 
especially when compared to less prevalence in colorectal and breast 
carcinoma (approximately 10-20%); the total incidence of anemia was 53,7%. In 
this case, patients that had been submitted to chemotherapy had a higher 
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incidence of anemia (63,7%) compared to concomitant chemo-radiotherapy 
(41,9%) or radiation therapy (19,5%) (Ludwig et al., 2004).   
In the case of lung cancer, cytotoxic chemotherapy is one of the main factors 
that contribute to the probability of developing or aggravating pre-existing 
anemia (Dowlati et al., 1997). Therefore, the incidence of anemia depends on 
the chemotherapy treatment that is used. The combination of cysplastin and 
etoposide, commonly used in the treatment of small cell lung carcinoma (SCLG) 
is associated with severe anemia in 16-55% of patients (Itri, 2000). In advanced 
non-small lung cell carcinoma (NSCLC), one of the firstly used treatments is 
paclitaxel and platinum therapies. However, the combination of these two drugs 
can induce anemia in approximately 78% of patients and, approximately 33% of 
patients can develop severe anemia (Langer et al., 1995). In these cases, the 
mechanism involved in chemotherapy-induced anemia includes direct 
myelosuppression and, in some cases, loss of renal function. These data are 
reinforced by the ECAS study since chemotherapy treatment induced mild to 
moderate anemia in 8-100% of patients suffering from NSCLC and 0-87% in 
those with SCLC (Ludwig et al., 2004). Moreover, severe anemia (Hb < 8 g/dL) 
and life-threatening anemia (Hb < 6.5 g/dL) occurs in 0-40% of patients with 
NSCLC and 0-55% in those suffering from SCLC (Groopman & Itri, 1999). 
Because of this, approximately 43% of patients with lung carcinoma were given 
blood transfusions, while patients suffering from breast carcinoma receiving 
blood transfusions did not exceeded 19% (Kosmidis & Krzakowski, 2005). 
Therefore, we can conclude that platinum compounds (like cysplatin or 
carboplatin) seem to particularly induce myelosuppression.  
Generally speaking, the hemoglobin values in the ECAS study are categorized 
between 10,0 and 11,9 g/dL. Nevertheless, the longer chemotherapy is used 
the higher is the risk of developing anemia. This fact was confirmed by 
progressive proportion of patients with low levels of hemoglobin (i.e. <10,0 g/dL) 
as the cycles increased (Ludwig et al., 2004). In fact, anemia was observed in 
19,5% of patients in the first cycle with an increased incidence to 56,7% on the 
fifth cycle of chemotherapy. If baseline hemoglobin level is approximately 15 
g/dL and subsequently these values are reduced by 2 g/dL during the first 3/4 
weeks of chemotherapy, 49% of patients are going to require a blood 
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transfusion to treat anemia at a certain stage during treatment. On the other 
hand, if a similar Hb decrease from a 11 g/dL baseline level occurs during the 
first cycle of treatment, practically all patients will need a transfusion (Langer et 
al., 2002). Therefore, it is necessary to determine the optimal cut-off value for 
the treatment of anemia, which is a critical criterion to maximize quality of life 
and possibly other outcomes in cancer patients. The ASH/ASCO guidelines 
recommend that treatment using erythropoietin starts when hemoglobin values 
decrease to <10,0 g/dL (Rizzo et al., 2002). Besides, when patients are 
symptomatic due to anemia and hemoglobin values are between 10 g/dL and 
12 g/dL, the decision of implementing the start of the treatment is at the doctor’s 
discretion (Ludwig et al., 2004). 
Furthermore, the ECAS study revealed that patients with lower hemoglobin 
values also had lower WHO Performance Scores when compared to those with 
higher hemoglobin values. 50,7% of patients with <8,0 g/dL hemoglobin had 2-4 
WHO scores, as did 40% of those with 8.0-9.9 g/dL hemoglobin. On top of 
which, almost a quarter (24,8%) of patients with 10,0-11,9 g/dL hemoglobin had 
2-4 WHO scores (Ludwing et al., 2004). These results can lead to a better 
understanding of anemia when associated with cancer therapy, thus optimizing 
the patient’s treatment and improving quality of life during that period. These 
results are reinforced by the Cella study that analyzed the use of Functional 
Assessment of Cancer Therapy (FACT) to assess the impact of fatigue or 
anemia in cancer patients’ QOL. Patients with Hb > 12 g/dL (defined as non 
anemic) felt less fatigue, better wellbeing and higher general levels of QOL, 
when compared to those who were not anemic (Cella, 1997). 
Moderate physical exercise can be a strategy to increase hemoglobin. In the 
specific case of breast cancer, women who undergo radiation therapy are prone 
to diminished erythrocyte levels during the months after treatment. As 
previously analyzed, this erythrocyte decrease appears to be associated to 
complications that include fatigue, anemia, depression and reduced physical 
functioning (Lucia et al., 2003). Furthermore, diminished erythrocyte levels 
seem to be connected to a decrease in the survival rate in some types of 
cancer. Drouin et al. (2006) studied the influence of moderately intense aerobic 
exercise and its positive effect in hemoglobin (HB), haematocrit (HCT) and red 
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blood cells (RBC) in women with breast cancer in stages 0 to 4 (Tis, N0, M0; to 
T0-4, N3-M0) subjected to a 7-week radiation therapy regimen (Drouin et al., 
2006). The exercise intervention consisted of walking 3 to 4 times a week, at an 
intensity between 50% and 70% CFmax. Through this research, investigators 
observed that moderately intense aerobic exercise during radiation therapy in 
breast cancer prevented the reduction of erythrocyte levels when compared to 
control group. Moreover, the authors verified a positive correlation between the 
peak of aerobic capacity and the final erythrocyte evaluation, corroborating the 
concept of the connection between erythrocyte level and improved physical 
capacity (Drouin et al., 2006).  
 
2.1.2 Peripheral Fatigue and Central Fatigue 
The main mechanisms of fatigue have been categorized in two principal 
components: peripheral fatigue and central fatigue. Peripheral fatigue is a result 
of the neuromuscular system’s inability to carry out a task in response to central 
stimulation. Two recent studies have analysed the effect of radiotherapy in 
neuromuscular fatigue. Monga et al. (1997) observed in prostate cancer 
patients diminished neuromuscular efficiency (a muscular function parameter) in 
the anterior skeletal muscle tibia’s fast fibres. The patients were submitted to a 
radiation treatment protocol with 68 to 70Gy in 34 to 38 fractions during a period 
of 7 to 8 weeks. However, when the effect of radiotherapy was studied, using 
certain psychometric scales, to ascertain the psychological and emotional state, 
and sleep parameters, no association was made between radiotherapy and 
clinical fatigue (Monga et al., 1997). Moreover, the same patients did not have 
diminished VO2max, assessed by modified Bruce protocol, which led to the 
conclusion that neuromuscular instead of cardiorespiratory factors contribute 
mostly to increased muscular fatigue. Therefore, 68 to 70Gy of ionizing 
radiation in the pelvic area of patients who are undergoing treatment for 
prostate cancer, emphasizes neuromuscular fatigue. In the majority of patients, 
the fatigue persisted 5 to 6 weeks after radiotherapy had ended, which may 
indicate that the nature of the fatigue presumably resulted from subtle lesions in 
the muscular structure. Authors speculate that ionizing radiation may have 
altered the integrity of the sarcolemma, sarcoplasma and/or the integrity of the 
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mitochondrial membranes (Monga et al., 1997). This alteration causes a 
disruption in the strength producing mechanisms and/or a calcium abduction by 
the sarcoplasma and by the Ca-ATPase, which entails a deficiency in the 
excitation-contraction process (Bigland-Ritchie et al., 1995). Furthermore, this 
alteration in the cytoskeleton can cause an electrolyte gradients’ imbalance in 
the cellular membranes, thus inducing a K+ accumulation in the extracellular 
medium (plasma). In the Agroyannis et al. (1992) study, it was observed that in 
21 patients with malignant tumours (lung, breast, endometrium and prostate), 
36 to 60Gy of radiation during 20 to 30 fractions of radiotherapy  caused a 
significant increase in the release of seric transferrin and TNF-. 
On the other hand, central fatigue affects the central nervous system and is the 
result of a progressive failure in the transmission of stimuli by the motoneuron. 
A study on patients with chronic fatigue syndrome demonstrated that a 
plasmatic free tryptophan increase can potentially lead to a high level of 
cerebral serotonin (5-HT) (Castell et al., 1999).The tryptophan and the 
branched-chain amino acids (BCAAs) compete to enter the brain through the 
same transport – albumin (Ryan et al., 2007). Several protocols that use 
exercise as a way to induce fatigue reveal that the increase of cerebral 5-HT 
levels during exercise is the result of a reduction of BCAAs, which allows the 
tryptophan to enter the brain through the hematoencephalic barrier. On top of 
which, exercise increases the concentration of plasmatic free fatty acids that 
bind with the albumin, causing an increase of free tryptophan in the plasma. 
Supporting this, research on animal models has demonstrated that 
concentrations of cerebral 5-HT increase during exercise, reaching the highest 
concentration at the point of fatigue (Ryan et al., 2007).  
 
 
2.1.3. Exercise and cancer related fatigue 
More recently, exercise has been tested in the treatment/reduction of cancer-
related fatigue (Dimeo, 2001; Winningham, 2001). Schwartz et al. (2001) 
showed that fatigue was significantly reduced on exercise days compared with 
non-exercise days. Furthermore, the amount of exercise, measured by the 
number of minutes of actual practice, was significantly associated with fatigue 
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levels. There is growing evidence that aerobic exercise programs can reduce 
fatigue in cancer patients receiving chemotherapy (Adamsen et al., 2004; 
Adamsen et al., 2006; Dimeo et al., 2003; Dimeo et al., 1999; Quist et al., 2006; 
Schwartz et al., 2001; Winningham et al., 1989). 
Mock et al. (2001) studied the effect of home-based exercise at least 90 min per 
week for three or more days in women with breast cancer who reported 
significantly less fatigue and emotional distress as well as higher functional 
ability and QOL than the women who were less active during treatment.  
The literature describes exercise as having potential importance in the 
quantitative reduction of fatigue. The qualitative data in this study highlight the 
experience of cancer patients having a comfortable sense of fatigue while 
simultaneously improving their physical form and increasing their strength. Data 
from Adamsen et al. (2004) describe different forms of fatigue in cancer 
patients.  The sensation of fatigue which results from exercising (i. e. exercise 
induced fatigue) is experienced as a positive and natural tiredness and is 
furthermore associated with an after-effect of improved physical well-being, 
tranquillity, release, relaxation, and, for some, typically improved sleep (Cella et 
al., 2002). It is a sense of fatigue that is desirable because the after-effects are 
familiar as they were experienced during sports activities prior to their illness 
(Watson & Mock, 2004). This contrasts with fatigue induced by chemotherapy 
which can be characterized as negative because of its connection with the 
experience of physical discomfort. It is not a sense of fatigue that is desired but 
rather is imposed on the body from the outside through medication, and usually 
leads to a passive physical state. Adamsen et al. (2004) showed that cancer 
patients can transform the nature of fatigue – from a negative chemotherapy 
induced fatigue into a positive exercise induced fatigue.  
The impact of exercise on fatigue was significant and reflects the effectiveness 
of low to moderate intensity regular exercise in maintaining functional ability and 
reducing fatigue in patients with breast cancer. Exercise was consistently 
associated with reducing fatigue the day of exercise and one day afterward over 
the first two cycles of chemotherapy in breast cancer patients (Schwartz et al., 
2001). However, current level of fatigue increased when exercise exceeded 60 
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Treatment Disease Detraining 
Fat igue  
Attenuated fatigue 
Physical Activity / exercise Sedentary habits 
State of “chronic” fatigue 
minutes, probably due to changes in nutrition and hydration states (Schwartz et 
al., 2001). 
In short, physical inactivity induces an accentuated loss of muscular mass and 
loss of cardiorespiratory capacity. Therefore, lack of physical activity causes a 
tendentiously perpetual condition of diminished activity leading to fatigue and 
vice-versa (Figure 1). This mechanism may explain persistent fatigue and 
physical performance impairment in several patients, even years after ceasing 
of treatment (Dimeo, 2000; Lucia et al., 2003).  
 
 
 
 
 
 
 
 
 
 
 
 
Image 1:  Effect of treatment, disease and detraining in Cancer Related Fatigue (Adapted from 
Rundle, (Rundle, 2005).   
In a cross sectional study, 3 years after breast cancer treatment, persistent pain 
and sensory disturbances remain clinically significant problems among 47% 
breast cancer patients who received surgery (Gartner et al., 2009). In fact, 
fatigue and pain overlap, and both seem to be additionally associated with 
mental health (Gartner et al., 2009).  
The cause of pain in cancer patients and in general, remains unclear. A 4 year 
follow-up showed an increase in pain symptoms in those women taking 
tamoxifen at baseline; in those reporting depression or stressful life events 
during the first 12 months after enrolment. Nevertheless, exercise at baseline 
had a beneficial effect on pain recovery (Rief et al., 2011). So, pain should be a 
major outcome in evaluations of cancer treatment and rehabilitation programs.  
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In 2009, with support from Siteman Cancer Centre and the Oncology Nursing 
Society, the ACSM convened an expert roundtable to review the literature on 
exercise in cancer survivors and issue guidelines for activity, along with 
recommendations on exercise testing and prescription (Schmitz et al., 2010). 
The ACSM guidelines for cancer survivors emphasis on returning to normal 
daily activities as quickly as possible after surgery and continuing these 
activities as much as possible during any adjuvant treatments (Wolin et al., 
2012).  
Low to moderate exercise interventions of variable duration seem to be the 
standards applied across existing studies. Predominantly, those studies have 
examined the effects of a single activity, e.g. cardiovascular training on 
stationary bicycles, rather than resistance to the exercise as the one of modality 
(Galvao & Newton, 2005).  More studies are needed to provide evidence of 
whether specific patient groups, at different stages of the disease and/or with 
different diagnoses and treatments, can benefit from exercise. So, due to the 
lack of evidence, no recommendations can be issued at present (Lucia et al., 
2003). 
A multidimensional 6 weeks high intensity exercise training design intervention 
in cancer patients with different types of solid tumours and haematological 
malignancies undergoing chemotherapy, increased VO2max in 16% and dynamic 
strength of 40%. Furthermore, it was observed a significant reduction in 
treatment-related symptoms and significantly improved their general well-being 
and quality of life specifically with a reduction of fatigue and pain (Adamsen et 
al., 2006). In accordance with these results, Kolden et al. (2002) verified 
through a supervised 16 week program involving cardiovascular, resistance and 
flexibility training, 1h three times a week in 40 sedentary women with breast 
cancer, an increase in strength of 36% and in cardiovascular capacity of 15%. 
These results suggest that cancer patients undergoing chemotherapy may 
benefit from a multidimensional exercise interventions. 
Knutsen et al. (2006) reported any adverse effects such as unintentional 
physical reactions, cardiac, or respiratory arrest, or hypotension during VO2max 
and 1RM strength test in cancer patients undergoing chemotherapy. The study 
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showed that patients felt significantly safer in performing the maximum physical 
capacity tests and in using their bodies in a 6 week high intensity training. 
 
 
 
2.2. Cancer, exercise and quality of life 
Investigation regarding exercise in cancer survivors began in the early 80’s but 
published articles became consistent in the late 90’s only. The Alberta 
University in Edmonton, Canada, by means of investigator Kerry Courneya, has 
been a driving force in clinical trials in this area (Courneya, 2003; Courneya et 
al., 2008; Courneya & Friedenreich, 2011).  
The positive effect and the advantage of exercise in cancer patients were 
described for the first time by (Winningham et al., 1989). 
Physical exercise is one of the foremost areas of research in cancer control with 
potential to improve the lives of cancer; the context “cancer survivor” indicates 
any person who has or had cancer, from the time of diagnosis onward (Ingram 
& Visovsky, 2007). The psychological and physical symptoms resulting from 
cancer and its treatments (e.g., pain, fatigue, nausea, vomiting, depression) will 
contribute to excessive patterns of rest and also contribute to immobility. Bed 
rest will precipitate muscle weakness, atrophy, and functional impairment 
(Ingram & Visovsky, 2007).  
Evidence of the benefits of exercise for cancer survivors has mounted steadily 
over the past in the areas of psychology and quality of life outcomes. Recently, 
improvements in physical functioning, body weight and composition, muscle 
strength and endurance (Quist et al., 2006), and immune function have been 
reported.  
The exercise interventions are low to moderately intense (exercise intensity 
between 55% and 85% HRmax) with very similar protocols throughout the 
various studies (Courneya & Friedenreich, 1999; Dimeo et al., 1999). These 
rules are in accordance with ACSM guidelines, that state that 6 to 7 weeks of 
training are enough to obtain significant muscular hypertrophy gains. As to the 
frequency of training, two to three weekly training sessions are sufficient to 
promote the desired adaptations (Garber et al., 2011).  
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Several clinical trials have studied the relationship between clinical exercise, 
quality of life and psychosocial parameters in cancer survivors. The exercise 
programs in the trials consisted mainly of 3 weekly sessions of moderate and 
vigorous exercise, with a duration that increased progressively up to 45` over a 
period of 3 to 4 months. These studies demonstrated that exercise reduced 
anxiety, depression, improved self-esteem and diminished fatigue-related 
symptoms (Herrero et al., 2006; Quist et al., 2006). 
One of the best direct indicators of cardio respiratory capacity is VO2max. This 
variable is an excellent indicator of a person’s health condition and an 
independent mortality predictor in healthy or unhealthy individuals (Garber et 
al., 2011). Initially, some authors alerted to the possibility that vigorous exercise, 
including maximal physical evaluation tests, could impair the cancer patient’s 
health during chemotherapy due to the administered drugs’ adverse effects. 
However, contrary to what was expected, the study carried out by Knutsen et al. 
did not observe adverse effects such as hypotension, cardiac or respiratory 
arrests, during the assessment of aerobic and muscular functions following 
maximum protocols (Knutsen et al., 2006). 
Obesity is a risk factor for some of the most common cancers in the western 
world, such as post menopausal breast cancer and colorectal cancer. This is 
one of the reasons why cancer patients are overweight or obese at the time of 
diagnosis (Brown et al., 2003). Furthermore, there is strong evidence that 
excessive weight increases the recurrence risk in several cancers, as well as 
increased mortality risk (Eheman et al., 2012). At present, the International 
Agency for Research on Cancer estimates that 25% of cancer cases are 
caused by excessive weight, obesity and a sedentary life (Ahlberg et al., 2003). 
The current tendency of increasing number of adults and children that are 
overweight or obese and, simultaneously, have low levels of physical activity 
makes the connection of their lifestyle with cancer a matter of public health 
(Campbell & McTiernan, 2007). Therefore, exercise has been used as a mean 
to reduce obesity and to promote a healthy lifestyle.      
Empirically, strength training is generally inappropriate for people with an illness 
as well as for cancer survivors, and for this reason there is still little investigation 
on the potentials of this type of training. However, several studies have 
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observed improved quality of life in cancer patients even when the exercise 
program is discontinued for a period of time due to a specific reason (anemia, 
infections and demotivation). An 8-week exercise program of aerobic training 
combined with strength exercises, with 3 weekly 90 minute sessions, in women 
with breast cancer, significantly increased muscular mass and reduced fat mass 
and these improvements were linked to an improved quality of life (EORTC 
QLQ-C30) (Herrero et al., 2007). On top of that, in breast cancer survivors, 
even after an 8-week detraining period QOL was not diminished, as were not 
dynamic force and specific functional tasks of muscular capacity. However, the 
same period of detraining reduced cardio respiratory capacity by ~6ml.Kg.min-1 
(VO2peak) (Herrero et al., 2007). Therefore, cardiorespiratory adaptations are 
quickly lost. Nevertheless, strength training should be integrated as a 
component in a training program since it attenuates muscular atrophy induced 
by treatment and sedentary habits in cancer survivors (Inui, 2002). In this case, 
ACSM guidelines recommend that 6 to 7 weeks of training are enough to obtain 
significant muscular hypertrophy gains. As far as frequency is concerned, 2 to 3 
weekly training sessions are sufficient for both men and women (Schmitz et al., 
2010). In fact, aerobic and strength training improves quality of life in a way that 
is practically unparalleled in patients with various types of cancer, that is to say, 
an increase of almost 43% in dynamic muscular force accompanied by a 21% 
increase in the improvement of QOL after 18 weeks of aerobic and strength 
training (De Backer, Van Breda, et al., 2007). 
In another recent study, during the hospitalization of patients submitted to high-
dose chemotherapy, an exercise program of aerobic resistance that consisted 
of pedaling for 30 minutes on a reclined cycle ergometer, reduced fatigue and 
loss of physical performance. On the other hand, chemotherapy-related 
complications, namely aplasia (quantity of neutrophils < 500/mL and platelets < 
20,000/mL) and duration of hospitalization, were significantly inferior in the 
trained group, when compared to the control group (Dimeo et al., 1999).   
In the specific case of prostate cancer treatment, the deprivation of androgens 
can cause an adverse effect – bone mineral density loss, progressing to 
osteoporosis. It is described that this bone mineral density loss, of 3 to 5% in 
the first years of treatment, results in a higher incidence of fractures 
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(Friedenreich, 2001). Therefore, not only has exercise an important role in 
preventing prostate cancer but it also prevents the adverse effects that can 
occur during therapy (Campbell & McTiernan, 2007). 
Since approximately 60% of cancer survivors are 65 years old or more, there 
has been an interest in studying the potentials of exercise in these ages. In fact, 
since aging is connected to a decline in neuromuscular function and diminished 
capacity to synthesize proteins, the scientific community questions whether the 
elderly are subject to physical exercise’s positive adaptations. Besides, studies 
in the last decades have demonstrated that the elderly revealed improved 
physiologic function and positive adaptations such as those that were observed 
in younger adults (Drouin, 2004). Exercise, in this type of population, requires 
some precautions in several situations due to some contraindications.  
Psychological factors also have an important function in the aetiology of cancer-
related fatigue’s genesis. In this particular case, depression is considered a 
contributing factor to fatigue in cancer patients. The effect of physical activity is 
not limited to improved muscular and cardiovascular functions. In fact, improved 
physical performance can increase a patient’s sensation of control, 
independence and self-esteem; this improved self-esteem can result in better 
social interaction, reduced anxiety and fear (Dimeo, 2000).  
Segal et al. (2001) did not observe any effect of structured exercise on aerobic 
fitness and in HRQOL in breast cancer patients during treatment. These results 
are, to some extend, in line with (Thorsen et al., 2005) who did not observed 
any beneficial effect on fatigue, mental distress and HRQOL parameters of the 
14-week supervised home-based training program intervention shortly after 
chemotherapy. The fact that patients performed multiple supervised activities by 
themselves could represent additional stress for them. However, VO2max 
increased by 6.4 ml/kg/min-1 in the patients in the interventions group and only 
3.1 ml/Kg/min-1 in the patients in the control group corresponding to 23% and 
10%, respectively) showing a beneficial effect on CRF in young and middle-
aged cancer patients. Opposite to this findings Segal et al. (2003) demonstrated 
a positive effect of a 12-week supervised strength-training program on fatigue 
and overall HRQOL in men receiving androgen deprivation for prostate cancer.  
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Dimeo, Fetscher, et al. (1997) observed a positive effect of an interval exercise, 
using a cycle ergometer in bed, on fatigue and psychological distress in cancer 
patients during hospitalization.  
Courneya et al. (2003) reported a positive effect on fatigue and in overall 
HRQOL in breast cancer patients several months after treatment. 
Burnham and Wilcox (Burnham & Wilcox, 2002) observed a significantly higher 
overall HRQOL improvement in the exercise group compared with the control 
group but mental distress between groups was the same.  
Mock et al. (1997) demonstrated a positive effect of a 6-week individualized 
self-paced progressive walking program on fatigue and anxiety in breast cancer 
patients during radiotherapy. However, there were no significant differences 
between the exercise group and the control group in depression.  
The magnitude of changes in mental distress, fatigue, and HRQOL parameters 
in trials in this area are not consistent. It is not clear enough whether these 
differences of outcome are the result of differences in the patients 
characteristics and/or the type and the timing of the intervention or if these 
variations are explained by different methods of assessment (Thorsen et al., 
2005).   
The application of the principles of exercise training (specificity, overload, 
progression, initial values, reversibility and diminishing returns) in a design of an 
exercise prescription ensures the most appropriate type and dose of exercise to 
promote de desired outcome (Campbell et al., 2011).  
De Backer et al. (2009) conducted a systematic review to summarize the 
research of previous studies that used resistance training with cancer patients. 
The duration of the resistance training programs ranged from 3 to 24 weeks, 
with an average of 12 weeks and most of them prescribed two or three sessions 
per week. Furthermore, most of the studies applied resistance with aerobic 
training. Few studies described the number of sets and repetitions, and among 
10 of them, intensities ranged from 30-60 to 60-85% of 1RM. With regard to 
aerobic exercises, treadmill walking and stationary cycling were the most 
frequently prescribed sessions. Intensities of aerobic exercises varied from 40% 
to 90% of heart rate maximum. Studies incorporating resistance training 
prescribed either exercises using machines or resistance bands (Spence et al., 
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2010). As outcomes measures, most of the studies assessed muscle strength 
(1RM), endurance tests (maximal number of repetitions at 60-75% of 1RM), 
hand grip tests. The results demonstrate that increases in muscular strength 
occur in women with breast cancer who receive resistance training (Loprinzi & 
Cardinal, 2012). 
Evidence suggests that health professionals might encourage breast cancer’s 
patients to increase physical activity in a consistent way during treatment, 
because regular practice of exercise, as soon as possible after surgery and 
during treatment, may reduce secondary effects. 
Patients with breast cancer should start to increase gradually their physical 
activity to a 150 minutes per week within an moderate intensity or to a 75 
minutes per week at a vigorous intensity as soon as they finish their 
chemotherapy or radiotherapy treatments; as well as patients reaching 
progressively the minimum exercise guidelines, should be persuaded to 
increase their physical activity level to 180 minutes per week of moderate 
intensity up to vigorous intensity, because these activity levels are necessary to 
prevent the recurrence of breast cancer (Holmes et al., 2005). 
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The main objective of the study was to examine the effect of 12 weeks of 
supervised exercise in physical capacity, lower and upper body strength and 
QOL, in breast cancer patients, during treatment.  
Primary outcome was measured through the change in cardiovascular 
fitness and strength and the evaluation of health related quality of life, 
between baseline and post intervention. 
 
A secondary objective of the study was to assess the feasibility of supervised 
exercise program and respective effects upon cancer related fatigue, in breast 
cancer patients, during treatment.  
Secondary outcome was assessed through the change VO2max, power 
output and in pain and fatigue symptoms between baseline and post 
intervention program. Results were compared with a control group. 
 
Another second objective of this study was to examine aerobic and muscle 
functional changes, induced by a 12 weeks combined aerobic and endurance 
exercise program, in breast cancer patients and compares it with healthy 
women.  
This outcome was assessed through the changes in physical 
components between baseline and post intervention program, using 
health results as reference. 
 
 
44 
 
 
 45 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4. Material and Methods
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Research Design 
This study examines the effects of exercise during cancer treatment on physical 
fitness (primary outcome). Secondary outcomes will be the effects on 
improvement of health related quality of life, reduction of pain and fatigue. This 
study is designed as a pragmatic randomised controlled trial, with two study 
arms: a group of voluntary patients with an exercise program in addition to 
usual care; acontrol group receiving usual care and maintaining their normal 
physical activity. The supervised exercise program is a 12-week progressive 
intensity programme.  
Measurements were made at baseline and repeated 12 weeks later - follow-up 
measurements. Moreover, at baseline and after the intervention program the 
results from the breast cancer patients are compared with a healthy group. 
 
 
Patients 
This clinical prospective study was conducted from October 2011 to May 2012. 
Participants were recruited in Mama Help - Support Centre for Breast Cancer 
Patients. A total of 51 breast cancer patients, aged from 32 to 67 years, 
receiving adjuvant treatments (chemotherapy, radiotherapy, endocrine therapy, 
or their combination) participated in this 12 week, controlled exercise 
intervention. All patients were operated previously submitted to surgery (either 
mastectomy or breast conserving surgery with sentinel lymph node biopsy, or 
axillary dissection). 
Patients participating in the study met the following eligibility criteria: female 
gender, women with confirmed stages I-III breast cancer, aged 30 - 70 years 
and not fullfiling the current American College of Sports Medicine guidelines for 
adequate physical activity (<150 min per week) (Garber et al., 2011). 
Furthermore, patients should also have received at least one cycle of 
chemotheraphy. Exclusion criteria were stage IV disease, the absence of 
systemic adjuvant therapy, pregnancy or lactation, severe cardiac disease 
(NYHA class III or more), myocardial infarction within 2 months, uncontrolled 
hypertension (blood pressure > 160/90 mm Hg), verified osteoporosis, other 
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serious illness or medical condition, which could contraindicate exercise, 
patients not capable of training (severe knee arthrosis, ligament or cartilage 
injuries at lower extremities), severe anemia (<8 g/dL) or platelet count lower 
then 50.109/L. The Karnofsky performance status (KPS) was used as an 
observer-rated measure of functional ability (Brown et al., 2005). The patients 
had a Karnofsky performance status of 60 or higher.  
All patients signed an informed consent. Participants were stratified by 
treatment and then randomly assigned into exercise and control groups (figure 
2). Subjects were also informed that participation in the study was voluntary, all 
data would be confidential, and that they were free to abandon the study at any 
time without incurring changes in their usual cancer treatment. 
 
 
 
 
Figure 2: Flow of breast cancer patients through the study. 
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The Healthy control group (n= 15) was essentially a convenience sample, 
selected to match the anticipated age and gender profile of the patients with 
breast cancer. These women were not known to have cancer.  
The ethical committee of Sports Faculty of University of Porto and the Ethical 
committee of Mama Help - Support Centre for Breast Cancer Patients approved 
the study protocol.  The project was carried out in accordance with Helsinki 
Declaration. 
 
Measurements made at baseline and at follow-up after the 12-week period 
 
Patient Function 
The Karnofsky performance status (KPS) was used as an observer-rated 
measure of functional ability. 
 
Body composition 
Fat mass percentage was calculated through bioelectrical impedance analysis 
(InBody 230 Biospac, Seoul, Korea). Body mass index (BMI) was calculated as 
weigth (kg) / height (m)2. 
 
Handgrip performance 
Maximal grip strength and fatigue resistance were measured using a 
mechanical handgrip dynamometer (Grip-D TKK5401, Tokyo, Japan). The 
elbow joint angle was flexed at a 90º angle with the wrist as close to 0º as 
possible. Trials were performed in an alternating bilateral sequence for a total of 
six attempts (three with each arm), and a rest period of 30 seconds was 
required between each trial to standardize test procedures. The patient was 
given clear instructions when to start and stop the contraction and was 
encouraged during the test to squeeze the handgrip as hard as possible. The 
mean of the three trials was calculated and averaged for each patient. We 
nominated the arm where the surgery was performed as the handrip C and the 
opposite as handrip D. 
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Functional muscle performance 
Functional muscle performance was determined using a sit-stand test. For this 
test, we used a straight-backed chair (40cm high) and asked each subject to sit 
and stand, at their fastest pace, during 30 seconds with their arms folded across 
the chest. The final test score is the number of times that the patient rises to a 
full stand from the seated position with arms folded within 30 seconds.  
 
Maximal isometric leg extension 
Maximal leg extension was measured using a strain gauge (Globus, Codogne, 
Italy). In a seated position, in a chair with a knee angle joint at 90º and harms 
folded across the chest, patients realized at a command signal, maximal 
strength with quadricipets up to force reached maximum values. Trials were 
conducted with three attempts with an interval of two minutes between them; 
the average of the three tests was used as reference value. 
 
Health-related quality of life 
The assessment of HRQOL was performed by using the European Organization 
for Research and Treatment of Cancer Core Quality of Life Questionary C30 
(EORTC QLQ-C30), which is a psychometrically instrument designed to be 
applicable to a broad range of cancer patients (Aaronson et al., 1993). The 
instrument has been evaluated with regard to both validity and reliability 
(Fayers, 2001). QOL was measured using the questionnaire developed by the 
European Organization for Research and Treatment of Cancer (EORTC): the 
EORTC QLQ-C30 (third version 3.0).  
The EORTC QLQ-C30 comprises five functional scales (physical, role, 
emotional, social, and cognitive), three symptom scales (fatigue, pain, nausea 
and vomiting), and six single items assessing additional symptoms commonly 
reported by cancer patients. It also includes two questions on patients overall 
quality of life and overall health condition, providing a global quality-of-life score.  
In the present study, the dimension of physical function, emotional function, role 
function, cognitive function and global quality of life were considered. 
Furthermore, symptoms of fatigue and pain were also analyzed. These scales 
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were transferred to a 0 to 100 scale, which was calculated by using the scoring 
manual provided by the EORTC (Fayers, 2001). For the physical function, 
emotional function, role funtion, cognitive function and global quality-of-life 
scales, a higher score indicates better level of functioning, whereas increasing 
values on the fatigue and pain scale indicate more symptoms. 
The breast cancer module is meant for use among patients varying in disease 
stage and treatment modality (i.e. surgery, chemotherapy, radiotherapy and 
hormonal treatment). The module comprises 23 questions assessing disease 
symptoms (arms symptoms and breast symptoms), side effects of treatment 
(surgery, chemotherapy, radiotherapy and hormonal treatment), body image, 
sexual functioning and future perspective. In the present study, for the BR23 
questionary the arm symptoms and body image were considered. The scoring 
approach for the QLQ-BR23 is identical in principle to that for the function and 
symptom scales.  
 
 
Cardiorespiratory fitness 
All cardiorespiratory exercise tests were performed under similar environmental 
conditions (temperature ~20 ºC; relative humidity 45 – 55%; barometric 
pressure – 720mmHg) on an electrically braked cycle ergometer (BH Fitness 
Tesis, Barcelona, Spain). After a warm-up period, of 5 min with no load, power 
output was increased from an initial value of 20 W by 10W .min-1. The cadence 
monitor was placed in view of the subject during each test, and an exercise 
cancer physiologist insured that they maintained the required pedalling cadence 
throughout the duration of the test. The test was terminated upon volitional 
exhaustion and/or when cadence could not be maintained at a minimum of 60 
rev.min-1. (Herrero et al., 2006) Subjects refrained from performing physical 
activity during the 24h-period before the tests. 
Expired respiratory gas fractions were measured using an open circuit breath –
by-breath automated gas-analysis system (Cortex, Metalyzer, 3B, Leipzig, 
Germany). Before each test, flow, volume and gases were calibrated. HR was 
measured and recorded every 5 seconds using a HR monitor (Vantage NV, 
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Polar Electro, Kempele, Finland) that was connected with the gas-analyzer 
system.  
Maximal oxygen uptake (VO2max) and peak respiratory exchange ratio 
(RERpeak) were recorded as the highest value obtained for any continuous 20-
second period. The workload eliciting the VO2 at ventilatory threshold (VO2VT) 
was determined using the criteria of an increase in both ventilatory equivalent 
oxygen (VE.VO2-1) and end tidal pressure of oxygen (PetO2), with no increase 
in the ventilatory equivalent of carbon dioxide (VE.VCO2-1).  
 
 
Description of the Exercise Intervention Program 
The patients in the intervention group received written information about some 
simple principles of training physiology. The exercise objectives, specified for 
breast cancer patients were set by literature search (Campbell et al., 2011; 
Herrero et al., 2006; Knutsen et al., 2006; Schmitz et al., 2010; Velthuis et al., 
2010) and by seeking advices from cancer caregivers. Moreover, the exercise 
methods were developed in close cooperation with physiotherapists 
experienced in reahabilitation programs for cancer. Based on results from 
medical and cancer history, physical examination, and initial physiological and 
pychological assessment, an individualized exercise prescription was 
developed. Before each training session, a cancer exercise specialist, asked 
each participant a series of questions that would clarify the need to alter the 
exercise intervention, if necessary. Questions focused on how the patient felt 
after the last exercise session, if patient had muscle soreness or specific 
problems that would affect training (Schneider et al., 2007). Each exercise 
program was individualized according to baseline health and fitness levels. 
Patients trained in groups of four to six members and each session was 
supervised by the same experienced investigator. The patients in the exercise 
group trained two times per week for a 60 minutes period. The 60 minutes 
exercise program include a warming up (5 minutes), aerobic and muscle 
strength (50 minutes) and a cooling down (5 minutes).  
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The exercise program was composed of combination of cardiovascular training 
(cycle-ergometer), strength training, balance and core training, patient-specific 
rehabilitation and flexibility which were classified as either high or low intensity. 
Heavy resistance training and stationary bicycling who rise significantly the 
heart rate were categorized as high-intensity activities whereas patient-specific 
rehabilitation and flexibility, requiring lower energy expenditure, were termed 
lower intensity activities. The program was conducted in in specially designed 
workout room located in Mama Help - Support Centre for Breast Cancer 
Patients.  
 
High intensity training 
At the beginning of the program, aerobic training consisted of pedaling on a 
cycle-ergometer for a 15 minutes at 70% of maximal heart rate (HRmax), during 
the first four weeks, observed during the pre-training cardiorespiratory test. After 
week 4, we increased 5 minutes per week to allow patients to complete 30 
minutes of continuous pedaling. For subjects with poorer physical condition, it 
was sometimes necessary to divide the first sessions into shorter time intervals 
to complete the 15 or 20 minutes workout in stationary bicycle (e.g., bouts of 5 
minutes). The aerobic training was intended to be near to the anaerobic 
threshold but mostly aerobic. Nevertheless, individual anaerobic threshold could 
have been exceeded temporarily during the training. 
Resistance training included exercise engaging major muscle groups (chest 
press, leg squat, leg calf rise, leg extension, adductor / adductor, abdominal 
crunch, arm extension, arm curl, dorsal). All exercises were performed through 
the full range of motion normally associated with the correct technique for each 
exercise. During the first 6 weeks, patients performed one and two set of 
exercises for large (e.g., Leg Squat) and small muscle groups (e.g. arm 
extension), respectively, and all sets were performed at a resistance that 
allowed 12 – 15 repetitions. Thereafter, the resistance used was individually 
adjusted and increased to allow the completion of 8-10 repetitions for four sets 
for large muscle groups and 3 sets for small muscle groups. Abdominal and 
lower back exercises were performed in 15-20 repetitions. 
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Steps aerobics exercises were also used in resistance training and consisted of 
several, typical step movements resulting in a total of 150-200 jumps (Thorsen 
et al., 2005). Moreover, Circuit-training consisted of 5 to 6 different vigorous 
exercises such as abdominal, squats, leg extension, chest press and leg calf 
rise. Duration of each circuit training movement varied from 30 to 40 seconds 
with half resting period between consecutive movements. During training 
sessions, the training intensity was occasionally monitored with heart rate 
measurements to ensure the consistency between self-rated and actual 
exertion levels.  
Furthermore, patients were advised to maintain their exercise intensity 
comparable to a level between 12 and 14 (slightly strenuous to strenuous) of 
the Borg scale, a numerical scale used to rate perceived exertion (Borg et al., 
1985). 
 
Low intensity training 
The exercise sessions concluded with an extremely low-intensity cool down that 
targeted all major muscle groups, as flexibility or balance exercises. Flexibility 
comprised some exercises that emphasized all major muscle groups.  
 
Contraindications 
In accordance with the guidelines and safety precautions defined by Dimeo et 
al. (1999), pre-exercise screening and monitoring was performed. Patients 
undergoing chemotherapy or radiotherapy and with one of the following criteria 
were instructed to interrupt physical training on the specific day: leukocyte <0.5 
x 109/L, hemoglobin <6mmol/L, thrombocyte concentration <20 x 109/L, 
respiratory frequency >20, pulse at rest <100 bpm, and temperature above 38 
ºC. In cases of infection, a pause in training was recommended until the patient 
had been asymptomatic for a day and then training can be slowly resumed 
(Pedersen & Saltin, 2006).  
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Control Group 
Patients assigned to the control group received usual care, i. e., no exercise 
intervention. They will be asked to mantain their habitual physical activity 
pattern but after completion of the present study, control subjects were offered 
participation in a rehabilitation programme for cancer patients (Schmitz et al., 
2010). 
 
 
Statistical Analyses 
Characteristics of the patients at baseline and after 12-weeks intervention were 
expressed either as means and standard deviations or proportions. Baseline 
differences in each characteristic between intervention group and control group 
were tested with unpaired sample t-tests and Pearson chi-squares tests. Paired 
sample t-tests were used to compare each characteristics over time (baseline 
and 12-week follow-up). General linear model (GLM) for repeated measures 
was used to compare each characteristic over time (baseline and 12-week 
follow-up) with group assignment and time x group interaction included as fixed 
effects. For each characteristic analyzed, change scores were calculated as the 
difference between baseline and 12-weeks values; the difference was then 
divided by the initial value to estimate percentage or relative change. None of 
the measures showed significant deviations from a normal distribution (Shapiro-
Wilk test). Significance level in all analyses was set at 0.05. Statistical analyses 
were conducted using SPSS version 20.0.  
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5. Results 
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Compliance and adherence to exercise program.  
The flow of participants through the study is illustrated in figure 2. Briefly, 82 
breast cancer patients were assessed for elibility when contacted personally, 
and 54 accepted to participate in the study. Forty three of the 54 were allocated 
in exercise intervention program and 11 on the control group. Despite the 
demanding nature of this exercise intervention, 40 of 43 patients (93%) were 
able to complete a 12-week exercise program, which indicates a high level of 
compliance. Three patients with breast cancer did not go onward within the 
exercise programme, after the baseline evaluation (7%): two of them justified 
with personal reasons, and the other one had no regular transport from home to 
the place where the program was being monitored. Within the control group, 
nine from the eleven patients who realized the baseline evaluation (81.8%) did 
execute the follow-up, and they concluded the evaluation in week 12.     
Demographic, anthropometric, body composition and descriptive characteristics 
are shown in Table 1. There are no significant differences between groups in 
any baseline characteristic except in treatment. Control group has, on average, 
a higher weight and BMI than the exercise intervention group. 
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Table 1: Baseline demographic characteristics, diagnosis and treatment according to group. 
  
Variables 
Intervention 
Group (n=40)
3
 
Control Group 
(n=9)
3
 
p 
Healthy 
Group 
(n=15) 
Age, y 48.9 (8.7) 49.7 (8.4) 0.805
1
 46.8 (9.1) 
Height, cm 159.3 (16.5) 163.9 (4.7) 0.418
1
 161.9 (4.9) 
Weight, Kg 63.3 (11.1) 70.9 (10.4) 0.073
1
 59.3 (8.1) 
IMC (kg/m
2
) 24.2 (4.0) 26.5 (4.3) 0.122
1
 22.6 (3.0) 
Percentage of fat 32.3 (7.6) 35.0 (8.5) 0.346
1
 18.7 (7.8) 
Karnofsky performance status 73.8 (12.9) 75.6 (7.3) 0.688
1
 100 
Smoking   0.263
2
  
    Smokers, n (%) 5 (12.5) 0 (0)  1 (6.7%) 
Lymphnode dissection   0.881
2
 NA 
    Yes, n (%) 32 (80.0) 7 (77.8)   
    No, n (%) 8 (20.0) 2 (22.2)   
Type of surgery    0.815
2
 NA 
    Breast conserving cirurgy, n (%) 14 (35.0%) 3 (33.3)   
    Mastectomy, n (%) 26 (65.0%) 6 (66.7)   
Treatment   <0.001
2
  
    Chemotherapy, n (%) 7 (17.5) 2 (22.2)  NA 
    Radiation therapy, n (%) 6 (15.0) 1 (11.1)  NA 
    Endocrine therapy, n (%) 27 (67.5) 6 (66.7)  NA 
Physical function   
    VO2max (ml/kg/min
-1
) 21.2 (3.5) 19.4 (3.3) 0.192
1
 NA 
    Power Output (W) 63.1 (11.7) 67.2 (19.5) 0.411
1
 NA 
    Ventilation (L/min) 38.3 (9.6) 42.7 (15.0) 0.261
1
 NA 
    VO2VE (ml/kg/min
-1
) 17.2 (3.2) 16.7 (2.2) 0.620
1
 NA 
    Handgrip right (kg) 24.7 (4.3) 23.4 (4.2) 0.403
1
 NA 
    Handgrip left (kg) 24.3 (3.8) 22.0 (3.7) 0.092
1
 NA 
    Sit-stand (#) 18.1 (5.1) 16.8 (3.6) 0.457
1
 NA 
    Leg Extension (kg) 34.9 (11.8) 32.0 (5.0) 0.484
1
 NA 
Quality of life function     
    Global Health Status 62.7 (17.4) 58.3 (19.9) 0.510
1
 NA 
    Physical Function 76.8 (13.5) 71.8 (16.9) 0.344
1
 NA 
    Role Function 69.2 (26.2) 53.7 (31.0) 0.130
1
 NA 
    Emotional Function 65.6 (24.3) 55.5 (30.9) 0.290
1
 NA 
    Cognitive Function 70.8 (28.9) 66.7 (27.6) 0.697
1
 NA 
    Social Function 65.4 (24.3) 51.8 (26.9) 0.144
1
 NA 
Quality of life symptoms     
    Fatigue 40.3 (22.2) 51.9 (26.1) 0.146
1
 NA 
    Pain 30.4 (25.0) 40.7 (18.8) 0.251
1
 NA 
BR-23     
    Body Image 73.3 (21.5) 69.4 (25.0) 0.636
1
 NA 
    Arm Symptons 23.3 (21.5) 27.1 (11.3) 0.610
1
 NA 
1
 independent t-test 
2 
Chi-square test 
3
 Data presented as average (standard deviation) 
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Table 2. Baseline and follow-up muscle strength and cardiorespiratory fitness components of breast cancer patients in supervised exercise program. 
Measures Increase, n (%) Decrease, n (%) No change, n (%) Baseline
1
 12-Week
1
 %Δ
2
 p 
VO2max (ml/kg/min
-1
) 36 (90.0) 1 (2.5) 3 (7.5) 21.2 (3.5) 24.8 (4.9) 17.0 <0.001 
Power Output (W) 37 (92.5) 1 (2.5) 2 (5.0) 63.1 (11.7) 92.5 (18.9) 46.6 <0.001 
Ventilation (L/min) 35 (87.5) 5 (12.5) 0 (0) 38.3 (9.6) 46.0 (10.5) 20.1 <0.001 
VO2VE (ml/kg/min
-1
) 29 (72.5) 7 (17.5) 4 (10.0) 17.2 (3.2) 19.9 (4.1) 15.7 0.001 
Handgrip right (kg) 32 (80.0) 8 (20.0) 0 (0.0) 24.7 (4.3) 25.6 (3.9) 3.6 0.072 
Handgrip left (kg) 22 (55.0) 17 (42.5) 1 (2.5) 24.3 (3.8) 24.1 (4.0) -0.8 0.565 
Sit-stand (#) 36 (90.0) 2 (5.0) 2 (5.0) 18.1 (5.1) 22.6 (5.3) 24.8 <0.001 
Leg extension (kg) 35 (87.5) 3 (7.5) 2 (5.0) 34.9 (11.8) 39.6 (13.9) 13.4 0.003 
1
Data presented as average (standard deviation) 
2
Data presented as percentage of change 
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Table 3. Baseline and follow-up health-related quality of life subscales (EORTC QLQ-C30/BR23) of breast cancer patients in the control group. 
Measures Increase (%) Decrease (%) No change (%) Baseline
1
 12 week
1
 %
2
 P 
EORTC QLQ-C30        
Global Health Status 23 (57.5) 7 (17.5) 10 (25) 62.7 (17.4) 72.5 (14.9) 9.8 0.001 
Physical Function 25 (62.5) 6 (15.0) 9 (22.5) 76.8 (13.5) 84.2 (10.5) 7.4 <0.001 
Role Function 21 (52.5) 3 (7.5) 16 (40) 69.2 (26.2) 85.8 (17.9) 16.6 <0.001 
Emotional Function 26 (65.0) 7 (17.5) 7 (17.5) 65.6 (24.3) 80.4 (15.3) 14.8 0.001 
Cognitive Function 22 (55.0) 4 (10.0) 14 (35.0) 70.8 (28.9) 82.9 (17.1) 12.1 0.001 
Social Function 25 (62.5) 5 (12.5) 10 (25.0) 65.4 (24.3) 82.9 (20.3) 17.5 <0.001 
Fatigue 29 (72.5) 3 (7.5) 8 (20.0) 40.3 (22.2) 23.9 (19.1) -16.4 <0.001 
Pain 35 (87.5) 0 (0.0) 5 (12.5) 30.4 (25.0) 10.0 (14.0) -20.4 <0.001 
BR23        
Body Image 30 (75.0) 2 (5.0) 8 (20.0) 73.3 (21.5) 82.5 (18.6) 9.2 0.003 
Arm Symptons 25 (62.5) 2 (5.0) 13 (32.5) 23.3 (21.5) 19.2 (17.4) -4.1 0.012 
1
Data presented as average (standard deviation) 
2
Data presented as score change. 
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Changes in Muscle and in Cardiovascular Fitness with 12 weeks 
supervised exercise 
Changes in muscle strength and physiological characteristics are shown in 
table 2 and figure 3. The majority of physical components increased 
significantly after 12 weeks supervised exercise (p<0.05) (VO2max: +17.0%, 
Power output: +46.6%; Ventilation: +20.1%; VO2 at ventilatory threshold: 
+15.7%; Sit-stand: +6.1%; Leg extension: 13.4%). No significant changes in 
handgrip in the arm where the surgery was performed  (p=0.565) and in the 
opposite arm (p=0.072) were found. After the intervention, more than seventy 
percent (VO2 at ventilatory threshold: 29/40), eighty percent (Ventilation: 35/40; 
Leg extension: 35/40) and ninety percent (VO2max: 36/40; power output: 37/40; 
sit-stand: 36/40) of breast cancer patients exhibited an improvement in these 
physical components (figure 3). 
 
 
Figure 3: Percentage of change from baseline to 12 week in VO2max, power output, ventilation, 
anaerobic threshold, handgrip, sit-stand test and leg extension in breast cancer patients. 
*Statistically significance difference (p<0.005). 
 
 
Changes in HRQOL with 12 weeks supervised exercise  
From baseline to 12 weeks supervised training (table 3 and figure 4), significant 
increases were observed in health-related quality of life measures (EORTC-
QLQ-C30) (p<0.05), with score changes rang from -20.4 to 17.5% (Table 3). 
Breast cancer patients showed significant changes in pain and fatigue (p<0.01) 
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with a decrease of 20.4-points (67.1%) and 16.4-points (40.7%) respectively. 
After the intervention, more than fifty percent (global health status: 23/40; role 
function: 21/40; cognitive function: 22/40), sixty percent (physical function: 
25/40; emotional function: 26/40; social function: 25/40; arm function: 25/40) 
and seventy percent (body image: 30/40) of breast cancer patients increased 
their health-related quality of life measurements. It is noticeable that more than 
seventy percent (Fatigue: 29/40) and eighty percent (Pain: 35/40) of the 
participants reported, respectively, less fatigue and pain. After the intervention, 
while 7.5% (3/40) exhibited more fatigue, none of the patients reported more 
pain.  
 
Figure 4: Score change from baseline to 12 week in quality of life, physical function, role 
function, emotional function cognitive function, fatigue and pain in breast cancer patients.  
*Statistically significance difference (p<0.005). 
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Figure 5. Percent of patients that increased, 
deacreased, or did not change in VO2max, 
power output sit-stand and leg extension, 
from baseline to 12 weeks of supervised 
exercise.  
Figure 6. Percent of patients that increased, 
deacreased, or did not change in global QOL, 
physical function, emotional function, fatigue 
and pain, from baseline to 12 weeks of 
supervised exercise.   
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Table 4. Baseline and 12-week muscle strength and cardiorespiratory fitness components in intervention group and control group. 
 Intervention group Control group GLM repeated measures 
Measures Baseline
1
 12-week
1
 %Δ
2
 Baseline
1
 12-week
 1
 %Δ
2
 Time
3
 Group
3
 Time*Group
3
 
VO2max (ml/kg/min
-1
) 21.2 (3.5) 24.8 (4.9) 17.0 19.4 (3.3) 20.9 (3.4) 7.7 <0.001 0.045 0.007 
Power Output (W) 63.1 (11.7) 92.5 (18.9) 46.6 67.2 (19.5) 70.5 (19.4) 4.9 <0.001 0.096) <0.001 
Ventilation (L/min) 38.3 (9.6) 46.0 (10.5) 20.1 42.7 (15.0) 44.4 (14.9) 3.9 <0.001 0.705 0.026 
VO2VE (ml/kg/min
-1
) 17.2 (3.2) 19.9 (4.1) 15.7 16.7 (2.2) 17.4 (2.6) 4.1 0.027 0.141 <0.001 
Handgrip right (kg) 24.7 (4.3) 25.6 (3.9)  3.6 23.4 (4.2) 22.9 (4.8) 2.1 0.734 0.163 0.265 
Handgrip left (kg) 24.3 (3.8) 24.1 (4.0) -0.8 22.0 (3.7) 21.1 (3.5) - 4.1 0.244 0.053 0.481 
Sit-stand (#) 18.1 (5.1) 22.6 (5.3) 24.8 16.8 (3.6) 19.0 (3.7) 13.0 <0.001 0.147 <0.001 
Leg extension (kg) 34.9 (11.8) 39.6 (13.9) 13,4 32.0 (5.0) 32.0 (4.8) 0 0.147 0.209 0.001 
1
Data presented as mean (standard deviation) 
2 
Data presented as percentage of change 
3
Data presented as p values 
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Table 5. Baseline and 12-week health-related quality of life subscales (EORTC QLQ-C30/BR23) in intervention group and control group. 
 Intervention group Control group GLM repeated measures 
Measures Baseline
1
 12-week
1
 S.Change Baseline
1
 12-week
 1
 S.Change Time
2
 Group
2
 Time*Group
2
 
EORTC QLQ-C30          
Global Health Status 62.7 (17.4) 72.5 (14.9) 9.8 58.3 (19.9) 67.6 (19.7) 9.3 0.002 0.401 <0.001 
Physical Function 76.8 (13.5) 84.2 (10.5) 7.4 71.8 (16.9) 74.8 (12.8) 3.0 0.025 0.087 <0.001 
Role Function 69.2 (26.2) 85.8 (17.9) 16.6 53.7 (31.0) 70.4 (27.4) 16.7 0.001 0.705 <0.001 
Emotional Function 65.6 (24.3) 80.4 (15.3) 14.8 55.5 (30.9) 55.4 (39.6) -0.1 0.117 0.022 <0.001 
Cognitive Function 70.8 (28.9) 82.9 (17.1) 12.1 66.7 (27.6) 75.9 (31.3) 9.2 0.005 0.511 <0.001 
Social Function 65.4 (24.3) 82.9 (20.3) 17.5 51.8 (26.9) 64.8 (25.9) 13.0 0.001 0.033 <0.001 
Fatigue 40.3 (22.2) 23.9 (19.1) -16.4 51.9 (26.1) 48.2 (28.4) -3.7 0.003 0.021 <0.001 
Pain 30.4 (25.0) 10.0 (14.0) -20.4 40.7 (18.8) 37.1 (29.8) -3.6 0.002 0.009 <0.029 
BR23          
Body Image 73.3 (21.5) 82.5 (18.6) 9.2 69.4 (25.0) 76.8 (20.8) 7.4 0.021 0.484 0.801 
Arm Symptons 23.3 (21.5) 19.2 (17.4) -4.1 27.1 (11.3) 23.4 (13.0) -3.7 0.041 0.541 0.901 
1
Data presented as mean (standard deviation) 
2 
Data presented as p values 
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Changes in muscle strength, cardiorespiratory fitness and HRQOL 
between intervention group and control group 
At follow-up, a significant main effect for time and a significant time by group 
interaction effect were evident for the majority of muscle strength and 
cardiorespiratory fitness measures (Table 4). From baseline to 12-weeks, there 
was a statistical significant increase in VO2max, power output, ventilation 
(p<0.001) and sit and stand (p<0.001). The significant results suggest that the 
time effects in the muscle strength and cardiorespiratory fitness measurements 
were different between intervention group and control group (Figure 7).  In the 
intervention group, mean values significantly improved (p<0.05). In the control 
group values remained rather constant at follow-up (p>0.05). In fact, from 
baseline to after 12-weeks, intervention group showed significantly greater 
changes in VO2max (17.0% versus 7.7%), power output (46.6% versus 4.9%), 
ventilation (20.1% versus 4.9%), VO2 at ventilatory threshold (15.7% versus 
4.1%), sit-stand (24.8% versus 13.0%) and leg extension (13.4% versus 0%) 
compared to control group. No significant intervention effects were observed for 
handgrip measures.  
 
Figure 7. Percentage of change from baseline to 12 week in VO2max, power output, sit-stand test 
and leg extension from exercise program and control group of breast cancer patients. 
*Statistically significance difference (p<0.005). 
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was evident for the majority of measurements. Across the intervention, there 
was a statistical significant increase in all values. Intervention group had a 
significantly higher increase in global health status (9.8 versus 9.3 points), 
physical function (7.4 versus 3.0 points), emotional function (14.8 versus -0.1 
points), cognitive function (12.1 versus 9.2 points), social function (17.5 versus 
13.0 points), body image (9.2 versus 7.4 points) and arm symptoms (-4.1 
versus -3.7 points) than control group. It was also observed a significant higher 
decrease in fatigue (-16.4 versus -3.7 points) and pain (-20.4 versus -3.6 
points). The significant interactions suggest that the time effects in the quality of 
life differed between intervention group and control group (Figure 8). Among 
intervention group, mean values significantly improved with the intervention 
(p<0.05), whereas they remained rather constant at follow-up in control group 
(p>0.05).  
 
 
 
Figure 8: Score change from baseline to 12 week in quality of life, physical function, role 
function, emotion function, cognitive function, social function, fatigue and pain in breast cancer 
patients intervention group and control group. 
QOL PF RF EF CF SF Fatigue Pain
Intervention 9,8 7,4 16,6 14,8 12,1 17,5 -16,4 -20,4
Control 9,3 3,0 16,7 -0,1 9,2 13,0 -3,7 -3,6
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Table 6. Baseline and 12-week muscle strength and cardiorespiratory fitness components in intervention group and healthy group. 
Measures Healthy group 
Intervention group Baseline differences 12-week differences 
Baseline 12-week Difference
1
 (%) p
2
 Difference
3
 
(%) 
p
4
 
VO2max (ml/kg/min
-1
) 30.7 (4.0) 21.2 (3.5) 24.8 (4.9) 9.5 (30.9%) <0.001 5.9 (19.2%) <0.001 
Power Output (W) 114.6 (20.4) 63.1 (11.7) 92.5 (18.9) 51.5 (44.9%) <0.001 22.2 (19.3%) <0.001 
Ventilation (L/min) 63.2 (11.8) 38.3 (9.6) 46.0 (10.5) 24.9 (39.4%) <0.001 17.2 (27.2%) <0.001 
VO2VE (ml/kg/min
-1
) 23.7 (2.9) 17.2 (3.2) 19.9 (4.1) 6.5 (27.4%) <0.001 3.7 (16.0%) 0.002 
Handgrip right (kg) 29.2 (3.5) 24.7 (4.3) 25.6 (3.9)  4.5 (15.4%) 0.001 3.6 (12.3%) 0.003 
Handgrip left (kg) 28.5 (2,7) 24.3 (3.8) 24.1 (4.0) 4.2 (14.7%) <0.001 4.4 (15.4%) <0.001 
Sit-stand (#) 27.4 (5.2) 18.1 (5.1) 22.6 (5.3) 9.3 (33.9%) <0.001 4.8 (17.5%) 0.04 
Leg extension (kg) 48.9 (10.2) 34.9 (11.8) 39.6 (13.9) 14.0 (28.6%) <0.001 9.3 (19.0%) 0.022 
1 
Difference between baseline intervention group values and healthy group values, then dividing each result by baseline intervention group values. 
2
p values obtained from the independent t-tests comparing baseline intervention group and healthy control group mean values. 
3 
Difference between 12 week intervention group values and healthy group values, then dividing each result by 12 week intervention group values. 
4
p values obtained from the independent t-tests comparing 12-week intervention group and healthy control group mean values. 
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Changes in muscle strength and in cardiorespiratory fitness 
Table 6 displays muscle strength and cardiorespiratory fitness components in 
intervention group at baseline and 12-weeks and compares each time with 
healthy group values. As expected, at baseline and 12-weeks, independent t-
tests showed significant differences in all measures favoring healthy group 
(p<0.05). At baseline the differences between both groups were approximately 
from 31% to 40% in cardiorespiratory components and from 34% to 28% in 
muscle strength measures. However, 12 weeks of supervised exercise 
intervention, resulted in significant improvements in strength and aerobic 
capacity in breast cancer patients (see table 2; except handgrip measures) and 
consequently resulted in a lower difference compared to the healthy group. The 
data collected after the 12-weeks, showed approximately 20% to 27% lower 
cardiorespiratory fitness in the intervention group. Regarding muscle strength 
measures, the differences compared to the healthy group were from 15% to 
19%.   
 
 
Figure 9: Comparison of percent of change decrease in VO2max, power output, sit stand test and 
leg extension from baseline to week 12, between healthy group and breast cancer patients in 
intervention exercise program.  
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Despite the demanding nature of this exercise intervention, 40 of 43 patients 
(93%) were able to complete a 12-week exercise program, which indicates a 
high level of compliance, very similar to previous studies comprising breast 
cancer patients (Cheema et al., 2008; Courneya et al., 2003; Nikander et al., 
2007). Moreover, the compliance is higher when compared to other studies 
involving patients with different diagnosis (Quist et al., 2006). The combination 
of a training facility at the Mama Help- Support Centre for Breast Cancer 
Patients with professional supervision, was crucial, to convince patients that the 
exercise program was a complement to the ongoing medical treatment. No 
major adverse effects and no major health problems were noted in the subjects 
of both groups, over the 12-week period.  
The number of studies examining the benefits of exercise for breast cancer 
patients, has tremendously increased, in recent years. However, the majority of 
published works show inadequacies in design regarding principles of exercise 
training, and also lack detailed exercice prescription and report of patients 
adherence to the programme (Campbell et al., 2011). Therefore, there is 
shortage of information for developing specific exercise prescription to reduce 
side effects of cancer treatment. As far as exercise intensity is concerned, it has 
been reported that texercise dose and reported adherence rate were 
significantly and inversely correlated (r=-0.62, p=0.002 for weekly dose; r=-0.82, 
p<0.001 for total dose) implying that lower prescribed dose of intervention 
presented greater adherence rate (Carayol et al., 2012).  
Our study shows that a 12-week planned supervised training program, 
combining resistance and cardio respiratory exercises, brings positive changes 
to cardiorespiratory components, strength, muscle function, and quality of life 
outcome in breast cancer patients. These results are important, as cancer 
related fatigue decreases the QOL, which can be maintained, even after 
treatment, in 30% of patients with cancer (Stasi et al., 2003). 
Several studies have shown that exercise may improve cancer patients' 
physical fitness and well-being (Cheema et al., 2008; Herrero et al., 2006; 
Nikander et al., 2007; Schneider et al., 2007; Schwartz et al., 2001). However, 
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most of these studies (Mustian et al., 2009; Saarto et al., 2012) were home-
based exercise, with little control over the amount and intensity of exercise 
undertaken, making results difficult to compare (Quist et al., 2006). Some 
studies involving exercise were randomized-controlled trials, with cancer 
patients undergoing chemotherapy (Adamsen et al., 2006; Courneya et al., 
2007; Dimeo, Fetscher, et al., 1997), radiotherapy (Karvinen et al., 2011) and 
and specifically breast cancer patients on adjuvant chemotherapy (Carayol et 
al., 2012; Courneya et al., 2007; Winningham et al., 1989). Most of the studies 
applied low-to-moderate exercise interventions (intensity between 55% and 
85% of maximal heart rate), which appears to be standard, across existing 
studies (Ingram & Visovsky, 2007). Resistance training is an important 
component of any training program (Lucia et al., 2003). It is still difficult to 
assess which categories of patients (stage of illness, diagnosis and treatment) 
would best benefit from exercise, at what intensity, and in which form (Quist et 
al., 2006). In our study, breast cancer patients with different stages of the 
disease and with different cytostatic treatments, were included in a program 
combining aerobic training with resistance training.  
 
Our results for VO2max are in accordance with studies of MacVicar et al. (1989) 
and Kolden et al. (2002) who found that an aerobic interval training cycle 
ergometer program, over a 10-week period, in 45 patients receiving 
chemotherapy for breast cancer, leads to significant improvement in VO2max. 
Similar increases (improvement of 17.4%) in VO2max were found in 53 
postmenopausal breast cancer survivors, who trained in cycle ergometer during 
3 weeks (Courneya et al., 2003). Quist et al. (2006) studied the effect of high-
intensity resistance and cardiovascular training during a 9h weekly intervention, 
during 6 weeks, in cancer patients undergoing chemotherapy. The results 
showed a 41.3% increase in muscular strength and 14.5% in aerobic fitness 
demonstrating that high-intensity workout is well tolerated and beneficial to 
cancer patients undergoing chemotherapy. Cancer patients in advanced stage, 
profited, significantly, from the heavy resistance training of larger muscle groups 
– 3 series of five to eight repetitions at 85-90% of 1RM, 3 times weekly. The 
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aerobic training of 10 minutes of intense periods on stationary bicycles, 
equivalent to the average of 85.1% of each patient’s maximum heart rate, led to 
a significant increase in VO2max. 
Furthermore, low to moderate intensity training (40-50% HRmax), seems to 
induce improvements in aerobic function, compared to a control group 
(Burnham & Wilcox, 2002). 
 
In our study, we verified an increase in in the VO2max of 17.5%, that is quite 
similar to the study of Thorsen et al. (2005) in which, during 14 training weeks, 
twice a week, for 30 minutes, at 60-70% of HRmax, VO2max improved by 23%, 
comparatively to the control group, who had an increase of only 10%. However, 
our results differ from this last study, since in Thorsen et al. (2005) the control 
group had a more evident reduction of fatigue (17.0 points), comparatively to 
the exercise group, in which the decrease was of  (5.8 points) - EORCT QLQ C-
30.  
VO2max attained during a graded maximal exercise, is considered the single best 
indicator of aerobic physical fitness (De Backer, Schep, et al., 2007). When 
expressed relative to body mass, VO2max is also an indicator of health status 
and predictor of mortality (Blair et al., 1996). In our study, the average values of 
VO2max were clearly below 30 ml/kg/min
-1, which reflects the poor physical 
condition and the need for breast cancer patients and survivors to engage in 
exercise training programs, to improve their VO2max values, and thus their 
overall health status (Schmitz et al., 2010).  
On the other hand, after 12 weeks of training, the increase in VO2max of 17.5% 
in the intervention group translated into a decrease in VO2max in a diminishing 
from from 44.8% to 23.7%, comparing to the healthy group. The implication of 
the alteration of the VO2max in the aerobic function, in survival, is not yet known. 
However, a prospective study with 6.213 patients with cardio vascular disease, 
showed that the increase of 1-MET in cardio respiratory capacity, increased 
survival by 12% (Myers et al., 2002). 
Exercise training counteractsnegative effects of cancer treatments and can 
improve cardiovascular efficiency, increase cardiac output and stroke volume, 
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decrease resting heart rate, lower exercise heart rate, and improve ventilation 
and transport of oxygen from the environment to the cell (Noakes, 2000).  
Hayward et al. (2004) found that exercise training preserved intrinsic 
cardiovascular function after treatment with various chemotherapeutics agents. 
These protective effects were associated with an exercise induced increase in 
endothelial nitric oxide syntheses, myocardial heat shock protein content, a 
prevention of chemotherapy-induced myocardial lipid per oxidation, and 
reduced mortality after treatment (Hayward et al., 2004). However, despite 
aerobic training, in 70 women with HER2-positive tumors, short course of 
adjuvant trastuzumab was associated with left ventricular dilation and 
decreased systolic function (Haykowsky et al., 2009). In addition, power output 
and VO2max were not different after training (Haykowsky et al., 2009). However, 
participants attended only 59% of prescribed sessions during 4 months, which 
is an insufficient number of sessions to achieve beneficial training adaptations. 
On the other hand, the VO2max increase in postmenopausal women may be 
more skeletal-muscle related, considering that the oxygen consumption may 
increase with training, without eccentric left ventricle hypertrophy capacity 
increases (Spina et al., 2000). Adaptations of skeletal-muscle with training, are 
partially due to the increase of (i) oxidative capacity increase, (ii) capillary 
density, (iii) glycogen storage capacity and also (iv) in the skeletal muscle of 
fibres type I (Lucia et al., 2003).  
 
Magnitude of change in cardiopulmonary function after treatment can be 
considerably larger than those found in other studies in breast cancer patients 
during treatment (Courneya et al., 2003). Courneya et al. (2003) surmised that 
perhaps the differences in outcomes were the result of differences in 
methodologies between investigations, or perhaps breast cancer survivors’ 
responded better to exercise after treatment. Nevertheless, breast cancer 
survivors respond differently to exercise, depending on where they are on the 
cancer phase of treatment (Schneider et al., 2007). So, it is important that 
exercise be individualized to specific needs of the cancer survivor, who already 
has a compromised system, to prevent exacerbation of physiological and 
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psychological toxicities that occur as a result of cancer treatments (Schneider et 
al., 2007).  
During chemotherapy, some studies show different results in cardiorespiratory  
exercise effects. Segal et al. (2001) show increases only in the VO2max 3.5 
ml/kg/min-1 in patients who were not under chemotherapy treatments. However, 
in the current study we observed an increase of 15.4% in VO2max in breast 
cancer patients undergoing chemotherapy, which are in line with the results of 
Quist et al. (2006) who found an increase of 14% in aerobic fitness after a 9-h 
weekly training program over 6 weeks. Moreover, during 6 months of aerobic 
training with a pace of 2 to 3 weekly sessions, women with breast cancer 
undergoing chemotherapy, with a maximum HR between 40 and 75%, 
improved time of VO2max by 17.8%, while the group of women who finished their 
treatments, improved time of VO2max by 28.0% (Schneider et al., 2007). 
Furthermore, moderate intensity reduced fatigue during and after treatment in 
breast cancer patients (Schneider et al., 2007).  
Besides the increase in VO2max, a significant observation of the results of this 
study is the outstanding increase in power output. It can be argued that an 
improvement in the cycle endurance time, may be more clinically relevant than 
an improvement in VO2max (Laviolette et al., 2008; Ong et al., 2004). Ong et al. 
(2004) analysed several outcomes in chronic obstructive pulmonary disease 
through several exercise protocols. After an intervention of 6 weeks of 
supervised exercise power output increased by 30% and endurance time by 
144% (p<0.001).  
 
In our study, lower body strength, evaluated by leg extension, increased 
significantly by 13.4% (p<0.001), which demonstrated that this is a lower 
increase than the one found in the study of Ohira et al. (2006) who verified an 
increase of 38% in leg press (p<0.001). However, our results are comparable 
with those obtained by Kolden et al. (2002) which involved supervised, 
structural group exercise program using resistance bands, dumbbells, and 
variable resistance machines. Contrary to our results, Nikander et al. (2012) did 
not observe any improvement in leg extension strength, which may be 
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explained by the fact that the present intervention did not include resistance 
training but aerobic impact only. On the other hand, functional tests may be 
more applicable than maximum force tests (1RM), as used in some studies 
(Adamsen et al., 2006; Quist et al., 2006) since the increase of dynamic 
maximum force may not be clinically relevant for those who survive, or cancer 
patients (Herrero et al., 2006), opposite to what we often verify with athletes. 
Due to this fact, the study of muscular functionality was put into practice using 
the sit-stand test, already validated for use in patients with cancer (Herrero et 
al., 2006). After follow-up and in accordance to these authors, we found a 
significant increase in sit-stand test by 24.8% (p<0.001). Winters-Stone et al. 
(2008) verified that sit-stand 30s test, age and (self-reported) physical activity, 
were independent factors in fatigue prediction.  
Individual reaction to training charges is one of the effects in the exercise 
adaptation. Some individuals can increase, significantly, from baseline to week 
12, independently of their age (Quist et al., 2006). Sometimes, low baseline 
values are justified by surgery procedures, a long stay in hospital and/or 
treatments (e.g. cytotoxic treatments >12 months). In our study, we achieved 
increases in strength of 100%, as was observed in other studies (Quist et al., 
2006). In the study of Quist et al. (2006),  
 
In our study, we did not find differences in upper-member strength, through the 
handgrip evaluation. In opposition to our results, weight training twice a week, 
for 6 months, improved body composition and 63% upper body strength (1-RM 
test in bench press), with improvements in physical global scores, in breast 
cancer survivors (Ohira et al., 2006). 
Furthermore, McKenzie & Kalda (2003) estimated the effect of 8-week 
combined aerobic in Monark Rehab Trainer arm-ergometer and resistance 
exercises, on QOL, and arm components with unilateral upper extremity 
lymphodema, secondary to treatment. Their results showed that an 
improvement in QOL and lymphedema was not affected by upper-body strength 
training exercises. Intense aerobic exercise, for 12 weeks, appeared to be well 
tolerated, as well as an effective training mode in breast cancer survivors, who 
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had recently completed heavy adjuvant treatments, such as chemotherapy. The 
mechanism by each weight training may be a sense of return to feeling in 
control of their bodies, that may translate into feeling greater efficacy in other 
areas of their lives (Ohira et al., 2006).  
The low intensity charge in our training program for upper body may have 
influenced the fact no significant differences had been found in strength follow 
up, throughthe handgrip. On the other hand, the fact that we did not apply an 
evaluation strength test of the upper body, with the Bench Press, was a 
limitation of this study.  
Additional studies should take place in this area, to determine the optimum 
training program, to enhance upper body strength. Some studies, with breast 
cancer patients with lymphedema, are excluded, since the investigators are 
concerned that it could affect performance and training (Herrero et al., 2006; 
Nikander et al., 2007). Moreover, there is a compelling evidence for the safety 
and benefits of exercise to decrease lymphodema risks, reduce symptoms, and 
increase strength (Schmitz et al., 2009).  
Besides, handgrip performance is not a consistent predictor as a credit to 
evaluate CRF (Kilgour et al., 2010). Maximal grip strength reflects the capacity 
of the muscles to generate a large force in a very short time (Bautmans et al., 
2007). Muscle performance is important during daily activities that need 
sustained activity (i.e. to lift, to carry or to manipulate objects), grip work might 
be the best test, which reflects the functional capacity, resulting from the 
development of a certain strength level, in relation to the time it can be 
maintained (Bautmans et al., 2007). The association between fatigue and 
maximum strength through the handgrip, looks weak but, when fatigue 
protocols are used, the association may increase (Stone et al., 2000). 
Therefore, for physical functioning, maximal strength and grip work (eventually 
corrected for body weight) might be the best parameter to measure the physical 
evaluation (Bautmans et al., 2007). Some discrepancies among studies could 
be partially explained by the variety of different types of tumours in studies, as 
well as age or body weight (Bautmans et al., 2007; Kilgour et al., 2010; Stone et 
al., 2000).  
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During radiation therapy for breast cancer, muscles of the chest wall may be 
irradiated, and a typical radiation dose used in breast cancer treatment is 1.8-
2.0 Gy/day, 5 days/week, over 6 weeks (total of about 54-60 Gy). These 
muscles include pectorals (major and minor), subclavius and anterior serratus. 
Depending on the irradiation treatment area, muscles of the back, particularly 
the rhomboid layer and underlying deep muscles, may be exposed to radiation 
as well. Common resistance exercises, like bench press, push ups and lat pull-
downs, involve chest wall and back muscles (Clarkson & Kaufman, 2010) and 
may be eventually affected due to side effects of radiotherapy. 
In our study, the muscle function values, handgrip and sit stand test, are clearly 
inferior to those of the Healthy control group, which, in a certain way, may be 
one of the reasons why, in baseline, the intervention and control group showed 
persistent fatigue and pain signs. In the study elaborated by Kilgour et al. 
(2010), upper and lower body muscle strength, had significant predictors of 
CRF. In a study with advanced lung cancer patients, when compared to healthy 
ones, it was found beyond correlation between fatigue and strength in leg 
extension, the best parameters which related to CRF were the 30s-timed sit-
stand tests and the KPS (p<0.001), showing that a lower functionality translates 
into a higher fatigue score (Brown et al., 2005).   
Considering the quadriceps muscle function in the several tests used to 
evaluate the functional performance in patients with cancer (e.g. sit-stand test, 
timed up and go, and 6-min walk test), there is, clearly, a necessity for studying 
the lower members strength in order to understand functional adaptations of a 
training program in patients with cancer (Kilgour et al., 2010). These elements 
demonstrate the intervention of efficacy in this study, as it was verified that 12 
weeks of training reduced the difference in leg extension from 40.1% to 23.5%, 
and, in the sit-stand test, the result varied from 51.3% to 21.2% comparing to 
the Healthy group.  
Intervention exercise time is a factor that may influence results. In a specific 
study about intervention time, cardio respiratory capacity parameters as well as 
those of QOL, were compared, using from 3 to 6 months interventions (Sprod et 
al., 2010). It was demonstrated that 3 months of training improved 
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cardiovascular endurance, fatigue and depressing symptoms, in women with 
breast cancer. However, only the group of patients with cancer who trained for 6 
months, showed an improvement of lung function, evaluated by FVC and FEV1, 
when comparing to the control group. On the other hand, although3-month 
training is considered to be sufficient to improve strength in leg press, 6 months 
of training allowed to increase strength even more (Sprod et al., 2010).  
Although in our study the intervention group had an increase in lower body 
strength of 13.4% (p<0.001), Drouin et al. (2006) found increases of 38% after 6 
months of training. So, we can speculate that if our exercise program was 
extended in time, we could find even more significant improvements in muscular 
function.  
Identically Sprod et al. (2010) verified that after 12 weeks of training, fatigue 
was substantially reduced, demonstrating that 12 weeks of training is an 
enough time period to promote decreases in fatigue. In a study by Herrero et al. 
(2006), sixteen breast cancer patients were randomly assigned to a training or 
to a non-exercise group. The results from patients in the exercise group were 
compared to those in a control group, over a short period of 8-week exercise 
program. The program consisted of 3 weekly sessions of 90 minutes, with 
resistance and aerobic training. VO2max improved by 3.9 ml/kg/min
-1 and 
performance in leg press improved (17.9Kg), demonstrating that a short 
exercise program improves fitness and QOL in women with breast cancer.   
 
In our study, outcomes related to quality of life, improved significantly after 
exercise intervention. We verified a difference of more than 10 points, in global 
health status, role, emotional, cognitive and social function, as well as in fatigue 
and pain. Besides, physical function improved by 7 points. In these cases, an 
increase of 20 points on what concerns fatigue and more than 15 points in pain 
reflects a very high increase. Since the control group had daily health care 
support during the intervention period, this group also improved the global 
quality of life and social functioning. 
However, in agreement with our study, patients in the intervention group had a 
slightly better outcome for some HRQOL dimensions than patients in the control 
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group (Courneya et al., 2003; Mock et al., 2001). These findings are consistent 
with Naumann et al. (2012), who reported an increase of more than 10 points in 
QOL, in individual home-based and group-based training, in breast cancer 
survivors, after 9 weeks of exercise. 
Contrary to our study, Thorsen et al. (2005) verified a slightly better outcome for 
some HRQOL dimensions in the control group than in patients in the 
intervention group. The magnitude of changes in mental distress, fatigue, and 
HRQOL parameters in trials in this area, are not consistent. It is not clear 
whether these disparities of outcome are the result of differences in patient 
characteristics and/or the type and timing of intervention, or whether these 
variations can be explained by different methods of assessment.  
The most frequently reported symptom, resulting from treatment, is fatigue, 
which may last months and years after treatment (Bower et al., 2009; Erickson, 
2004; Ryan et al., 2007; Stasi et al., 2003). Cardiovascular toxicity can result in 
left ventricular dysfunction evidences, by an increase time to peak filling of the 
left ventricle, lower left ventricular ejection fraction, abnormal left ventricular 
contractility, reduced cardiac output and stroke volume, weak lead to lower 
oxygen and nutrition delivery (Brockstein et al., 2000; Gianni et al., 2001). 
Furthermore, pulmonary toxicity can occur as a result of cancer treatments and 
lead to shortness of breath, decrease of total lung capacity, vital capacity, 
inspirable capacity and decreased diffusion capacity, which, in turn, can 
compromise oxygen delivery and carbon dioxide removal (Brockstein et al., 
2000). With the increasing prevalence of cancer fatigue and treatment toxicities 
on the quality of life, determining how to manage and promote efficacious 
strategies for overcoming these alterations should be investigated during and 
after cancer treatment (Schneider et al., 2007).  
In the present study, exercise induced a pronounced decrease in fatigue and 
pain symptoms, which is in line with literature results referring that exercise may 
help to manage fatigue during and after treatments (Adamsen et al., 2004; 
Dimeo, Stieglitz, et al., 1997; Dimeo et al., 1999; Mock et al., 2005; Mock et al., 
2001; Stricker et al., 2004). However, the alteration of this symptom should be 
interpreted with some prudence. We use the symptom scale fatigue from 
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EORTC QLQ C-30 but, probably, it is important the use of a domain-specific 
instrument when fatigue is the primary outcome. Knobel et al. (2003) validated 
the fatigue scale in EORTC QLQ C-30 against the Fatigue questionnaire, the 
latter measuring both physical and mental fatigue. The analysis demonstrated 
that the fatigue scale in EORTC QLQ C-30 correlated higher with the physical 
fatigue scale (r=0.67 to 0.75) than with mental fatigue scale (r= 0.49 to 0.61). 
Fatigue measured by EORTC QLQ-C30 does not differentiate between acute 
and chronic fatigue (Thorsen et al., 2005). So, these authors recommend for 
studies with fatigue as defined end point,, a domain-specific instrument, which 
is more suitable to evaluate fatigue (Stone et al., 1998). Besides, in patients 
with advanced lung cancer, a correlation between FACT-Fatigue questionnaire 
and EORTC QLQ C-30 fatigue scales (r=0.712; p<0.001) was verified, showing 
that the questionnaire which was used in this study may help to understand the 
fatigue intensity in our work.   
In our program, patients in the intervention program reported less fatigue than 
patients in the control group, suggesting that exercise may reduce fatigue. 
Nevertheless, in the healthy control group, fatigue was not evaluated. After 
radiotherapy, Smets, Visser, Willems-Groot, Garssen, Oldenburger, et al. 
(1998) concluded that fatigue in breast cancer patients increased by 46% 
compared to a healthy control group. 
 
Moreover, after 9 months in disease-free patients, 26% of patients worried 
about their fatigue and, patients' overall quality of life was negatively related to 
fatigue (r = -0.46) and was significantly associated with gender, physical 
distress, pain rating, sleep quality, functional disability, psychological distress 
and depression, but not with medical or treatment-related variables (Smets, 
Visser, Willems-Groot, Garssen, Schuster-Uitterhoeve, et al., 1998). On the 
other hand, Geinitz et al. (2001) observed an increase in fatigue during 5 weeks 
of adjuvant radiotherapy in patients with breast cancer. Nevertheless, fatigue 
returned to pretreatment levels 2 months after treatment. No evidence was 
found about anxiety, depression, serum levels of IL-1beta, IL-6, tumor necrosis 
factor-alpha, or declining hemoglobin levels being responsible for the treatment-
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induced fatigue. Fatigue is common in depression, and both fatigue and 
depression are common in cancer patients (Stone et al., 1998). In some 
studies, consistent associations were found between fatigue and psychological 
distress (Stone et al., 2000). Moreover, Stone et al. (2000) found an association 
between fatigue severity and global quality of life suggesting that fatigue is an 
important contributor to quality of life in both health and disease, and has a high 
impact on the well-being among cancer patients. 
Contrary to our study, Thorsen et al. (2005) did not observe any beneficial effect 
on fatigue, mental distress and HRQOL parameters from the 14-week 
supervised home-based program training intervention shortly after 
chemotherapy. The fact that patients themselves performed multiple supervised 
could represent additional stress. However, VO2max increased by 6.4 ml/kg/min
-1 
in patients in the intervention group and only 3.1 ml/Kg/min-1 inpatients in the 
control group, corresponding to 23% and 10%, respectively), showing a 
beneficial effect on CRF in young and middle-aged cancer patients.  
The dose-effect relationship of exercise with fatigue needs more investigation. 
Nevertheless, some results revealed that a greater decrease in fatigue and an 
increase in QOL were observed with weak targeted exercise doses, <12MET 
h/week, as well as with long duration interventions (>18weeks) for QOL 
(Carayol et al., 2012). These findings generate the hypothesis that the 
prescription of a 20-week exercise program targeting 8-10 MET h/week could 
be well adapted for patients with breast cancer receiving adjuvant therapy 
(Carayol et al., 2012). In this case, combined aerobic and resistance (2 
sessions of moderate intensity aerobic exercise and one resistance session for 
principal muscular groups) during 30-45 minutes is recommended (Carayol et 
al., 2012). In our program, each exercise session had a limit time of 60 minutes, 
because the fatigue state may be aggravated by longer sessions (Schwartz et 
al., 2001). The reason for this is unclear, perhaps prolonged exercise provokes 
muscular fatigue and the feeling of fatigue associated with changes in nutrition 
and hydration states can increase the sensation of the current level of fatigue.  
Determining the optimal dose of exercise to reduce fatigue is elusive. In our 
study, women were instructed to exercise at an intensity of 70-85% of VO2max 
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but it was important that intensity was symptom limited. This exercise intensity 
was acceptable for breast cancer patients and did not worsen their symptoms 
during exercise. Schwartz et al. (2001) showed that fatigue was significantly 
reduced on exercise days compared with non-exercise days. Furthermore, the 
amount of exercise, measured as the number of minutes exercised, was 
significantly associated with fatigue levels. In a meta-analysis, the authors 
observed a positive relationship, meaning that larger amounts of targeted 
aerobic activity were associated with substantial QOL improvements, but the 
studies included various cancer sites, both controlled and uncontrolled trial and 
mixed intervention periods with most of the studies involving post adjuvant 
therapy intervention (Ferrer et al., 2011).  
 
In our study, women did not show an increase in body weight (not an outcome 
measure of our study). Nevertheless, besides being a quality of life contributor, 
exercise may also be a strategy for weight control since weight gain is common 
in both pre and postmenopausal women after diagnosis (Demark-Wahnefried et 
al., 2000) as well as during and after adjuvant treatments (Harvie et al., 2004; 
Sestak et al., 2012) and during the five-year follow-up (Makari-Judson et al., 
2007). Furthermore, the weight gains also tend to be linked to an increase in fat 
mass and the recent findings of Winters-Stone et al. (2008) showed that higher 
percentage of body fat reported more fatigue compared to leaner women. 
Moreover, using separate correlation analysis, using lean mass and fat mass, 
the later was significantly and positively associated with fatigue rather than lean 
mass (Winters-Stone et al., 2008). Upon diagnosis, and as a consequence of 
receiving treatment, being overweight or obese elevates risk up to 4-fold of 
developing multiple other diseases such type II diabetes, asthma, chronic back 
pain, osteoarthritis and cardiovascular disease (Rock & Demark-Wahnefried, 
2002). A meta-analysis included 43 studies that enrolled women diagnosed with 
breast cancer between 1963 and 2005 with a sample size ranged from 100 to 
42 4168. demonstrated that obesity is associated with poorer overall and breast 
cancer-specific survival (Protani et al., 2010). Weight gain is critical to patients, 
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as it relates to body image, but it is also a risk factor for impairment and poorer 
outcomes of treatment (Demark-Wahnefried et al., 2012). 
Weight control in women with breast cancer is important because the weight 
(BMI> 25.0) may increase the lymphedema probability. In the study of Swenson 
et al. (2009), through the multivariable analysis, axillary radiation, more 
extensive surgery, chemotherapy were predictive of lymphedema but, the only 
factor significantly associated with lymphedema, was overweight (p = 0.022). 
Being overweight is an important modifiable risk factor for lymphedema. 
Furthermore, the results indicate a lower lymphedema incidence in women with 
breast cancer who were submitted to resistance training strength (Swenson et 
al., 2009).  
 
The main strengths of the present study are the several measurements of 
physical performance and HRQOL. Opposite to other intervention studies of  
exercise, we chose a multi-structured exercise program, supervised in clinical 
context. We pretended to adequate the individuality of the exercise and to apply 
the principles of training in each exercise sessions, as the answer to exercise 
and to treatment varies among patients with breast cancer. The exercise 
program also intended to reduce the drop out percentage and to increase 
motivation for physical exercise practice, during and after treatment.  
A high adhesion to the programwas evident, which also confirms that women 
with breast cancer are able to tolerate high intensity aerobic exercises. To our 
knowledge, this is one of the first studies which analyses and compares the 
muscle and aerobic fitness through a multidisciplinary exercise program using a 
healthy control group. These results may be important for future studies with the 
outcome of returning to work since a poor physical condition may impair the 
productivity. 
The main limitation of the study is the small sample size and the heterogeneity 
of the case group due to variations in adjuvant treatments. A larger sample 
would also allow the possibility to access the relationship between the amount 
and intensity of exercise and respective changes in outcome. Using a fatigue 
specific questionnaire as the FACT-Fatigue, would help to have a better 
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understanding of the different fatigue categories and show a more solid analysis 
of the fatigue changes during the intervention. Using a fatigue protocol will 
probably give more information about the effect of a training program in breast 
cancer patients, with the aim to evaluate the strength of the upper members.   
 
The results of this study demonstrate the importance of exercise to reduce 
fatigue in women with breast cancer during treatment. Although in opposition to 
standard practice, it appears that women with breast cancer who are regular 
exercisers should be encouraged to continue their exercise program and 
women who are not regular exercisers should be given guidance and instruction 
to begin an exercise program. 
 
 
 
88 
 
 89 
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In conclusion, the results of the current study suggest that exercise supervised 
intervention program during 12 weeks increase cardiorespiratory fitness, 
strength and health related quality of life in breast cancer patients. Among the 
several physical components, the most responsive index, as measured by the 
percentage of change from baseline, was power output. The patients 
experienced a significant reduction in treatment-related fatigue and pain 
symptoms and significantly improved physical function. The observed changes 
in questionaire scores with 12 weeks supervised exercise reached clinical 
significance in several dimensions scores. The exercise was important to 
enhance both emocional and social functioning on top of physical 
improvements. 
Supervised aerobic training combined with strength training in this study support 
the potential that exercise is a safe, effective and a beneficial intervention 
strategy for improving physical fitness and health related quality of life in breast 
cancer patients during treatment.  
Ours findings also suggest that multidimensional exercise training should be 
recommended for breast cancer patients during treatment. 
 
 
92 
 
 
93 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
8. References 
 
 
 
94 
 95 
Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., 
Filiberti, A., Flechtner, H., Fleishman, S. B., de Haes, J. C., & et al. 
(1993). The European Organization for Research and Treatment of 
Cancer QLQ-C30: a quality-of-life instrument for use in international 
clinical trials in oncology. J Natl Cancer Inst, 85(5), 365-376. 
Adamsen, L., Midtgaard, J., Andersen, C., Quist, M., Moeller, T., & Roerth, M. 
(2004). Transforming the nature of fatigue through exercise: qualitative 
findings from a multidimensional exercise programme in cancer patients 
undergoing chemotherapy. Eur J Cancer Care (Engl), 13(4), 362-370. 
Adamsen, L., Quist, M., Midtgaard, J., Andersen, C., Moller, T., Knutsen, L., 
Tveteras, A., & Rorth, M. (2006). The effect of a multidimensional 
exercise intervention on physical capacity, well-being and quality of life in 
cancer patients undergoing chemotherapy. Support Care Cancer, 14(2), 
116-127. 
Agroyannis, B., Kouvaris, J., Tzanatos, H., Chondros, K., Stringou, E., 
Damatopoulou, A., Dalamangas, A., Koutsikos, D., & Papavasiliou, C. 
(1992). Influence of radiation treatment on serum transferrin and tumor 
necrosis factor-alpha. Anticancer Res, 12(5), 1757-1759. 
Ahlberg, K., Ekman, T., Gaston-Johansson, F., & Mock, V. (2003). Assessment 
and management of cancer-related fatigue in adults. Lancet, 362(9384), 
640-650. 
Anderson, W. F., Chatterjee, N., Ershler, W. B., & Brawley, O. W. (2002). 
Estrogen receptor breast cancer phenotypes in the Surveillance, 
Epidemiology, and End Results database. Breast Cancer Res Treat, 
76(1), 27-36. 
Bastani, P., & Ahmad Kiadaliri, A. (2011). Health-related quality of life after 
chemotherapy cycle in breast cancer in Iran. Med Oncol, 28 Suppl 1, 
S70-74. 
Bautmans, I., Gorus, E., Njemini, R., & Mets, T. (2007). Handgrip performance 
in relation to self-perceived fatigue, physical functioning and circulating 
IL-6 in elderly persons without inflammation. BMC Geriatr, 7, 5. 
 96 
Bigland-Ritchie, B., Rice, C. L., Garland, S. J., & Walsh, M. L. (1995). Task-
dependent factors in fatigue of human voluntary contractions. Adv Exp 
Med Biol, 384, 361-380. 
Blair, S. N., Kampert, J. B., Kohl, H. W., 3rd, Barlow, C. E., Macera, C. A., 
Paffenbarger, R. S., Jr., & Gibbons, L. W. (1996). Influences of 
cardiorespiratory fitness and other precursors on cardiovascular disease 
and all-cause mortality in men and women. JAMA, 276(3), 205-210. 
Borg, G., Ljunggren, G., & Ceci, R. (1985). The increase of perceived exertion, 
aches and pain in the legs, heart rate and blood lactate during exercise 
on a bicycle ergometer. Eur J Appl Physiol Occup Physiol, 54(4), 343-
349. 
Bower, J. E., Ganz, P. A., Tao, M. L., Hu, W., Belin, T. R., Sepah, S., Cole, S., 
& Aziz, N. (2009). Inflammatory biomarkers and fatigue during radiation 
therapy for breast and prostate cancer. Clin Cancer Res, 15(17), 5534-
5540. 
Brenner, H., Gondos, A., & Arndt, V. (2007). Recent major progress in long-
term cancer patient survival disclosed by modeled period analysis. J Clin 
Oncol, 25(22), 3274-3280. 
Brinton, L. A., Sherman, M. E., Carreon, J. D., & Anderson, W. F. (2008). 
Recent trends in breast cancer among younger women in the United 
States. J Natl Cancer Inst, 100(22), 1643-1648. 
Brockstein, B. E., Smiley, C., Al-Sadir, J., & Williams, S. F. (2000). Cardiac and 
pulmonary toxicity in patients undergoing high-dose chemotherapy for 
lymphoma and breast cancer: prognostic factors. Bone Marrow 
Transplant, 25(8), 885-894. 
Brown, D. J., McMillan, D. C., & Milroy, R. (2005). The correlation between 
fatigue, physical function, the systemic inflammatory response, and 
psychological distress in patients with advanced lung cancer. Cancer, 
103(2), 377-382. 
Brown, J. K., Byers, T., Doyle, C., Coumeya, K. S., Demark-Wahnefried, W., 
Kushi, L. H., McTieman, A., Rock, C. L., Aziz, N., Bloch, A. S., Eldridge, 
B., Hamilton, K., Katzin, C., Koonce, A., Main, J., Mobley, C., Morra, M. 
 97 
E., Pierce, M. S., & Sawyer, K. A. (2003). Nutrition and physical activity 
during and after cancer treatment: an American Cancer Society guide for 
informed choices. CA Cancer J Clin, 53(5), 268-291. 
Burnham, T. R., & Wilcox, A. (2002). Effects of exercise on physiological and 
psychological variables in cancer survivors. Med Sci Sports Exerc, 
34(12), 1863-1867. 
Burstein, H. J., Prestrud, A. A., Seidenfeld, J., Anderson, H., Buchholz, T. A., 
Davidson, N. E., Gelmon, K. E., Giordano, S. H., Hudis, C. A., Malin, J., 
Mamounas, E. P., Rowden, D., Solky, A. J., Sowers, M. R., Stearns, V., 
Winer, E. P., Somerfield, M. R., & Griggs, J. J. (2010). American Society 
of Clinical Oncology clinical practice guideline: update on adjuvant 
endocrine therapy for women with hormone receptor-positive breast 
cancer. J Clin Oncol, 28(23), 3784-3796. 
Campbell, K. L., & McTiernan, A. (2007). Exercise and biomarkers for cancer 
prevention studies. J Nutr, 137(1 Suppl), 161S-169S. 
Campbell, K. L., Neil, S. E., & Winters-Stone, K. M. (2011). Review of exercise 
studies in breast cancer survivors: attention to principles of exercise 
training. Br J Sports Med. 
Carayol, M., Bernard, P., Boiche, J., Riou, F., Mercier, B., Cousson-Gelie, F., 
Romain, A. J., Delpierre, C., & Ninot, G. (2012). Psychological effect of 
exercise in women with breast cancer receiving adjuvant therapy: what is 
the optimal dose needed? Ann Oncol. 
Castell, L. M., Yamamoto, T., Phoenix, J., & Newsholme, E. A. (1999). The role 
of tryptophan in fatigue in different conditions of stress. Adv Exp Med 
Biol, 467, 697-704. 
Cella, D. (1997). The Functional Assessment of Cancer Therapy-Anemia 
(FACT-An) Scale: a new tool for the assessment of outcomes in cancer 
anemia and fatigue. Semin Hematol, 34(3 Suppl 2), 13-19. 
Cella, D., Lai, J. S., Chang, C. H., Peterman, A., & Slavin, M. (2002). Fatigue in 
cancer patients compared with fatigue in the general United States 
population. Cancer, 94(2), 528-538. 
 98 
Cheema, B., Gaul, C. A., Lane, K., & Fiatarone Singh, M. A. (2008). 
Progressive resistance training in breast cancer: a systematic review of 
clinical trials. Breast Cancer Res Treat, 109(1), 9-26. 
Chirikos, T. N., Russell-Jacobs, A., & Cantor, A. B. (2002). Indirect economic 
effects of long-term breast cancer survival. Cancer Pract, 10(5), 248-255. 
Clarkson, P. M., & Kaufman, S. A. (2010). Should resistance exercise be 
recommended during breast cancer treatment? Med Hypotheses, 75(2), 
192-195. 
Courneya, K. S. (2003). Exercise in cancer survivors: an overview of research. 
Med Sci Sports Exerc, 35(11), 1846-1852. 
Courneya, K. S., Booth, C. M., Gill, S., O'Brien, P., Vardy, J., Friedenreich, C. 
M., Au, H. J., Brundage, M. D., Tu, D., Dhillon, H., & Meyer, R. M. 
(2008). The Colon Health and Life-Long Exercise Change trial: a 
randomized trial of the National Cancer Institute of Canada Clinical Trials 
Group. Curr Oncol, 15(6), 279-285. 
Courneya, K. S., & Friedenreich, C. M. (1999). Physical exercise and quality of 
life following cancer diagnosis: a literature review. Ann Behav Med, 
21(2), 171-179. 
Courneya, K. S., & Friedenreich, C. M. (2011). Physical activity and cancer: an 
introduction. Recent Results Cancer Res, 186, 1-10. 
Courneya, K. S., Mackey, J. R., Bell, G. J., Jones, L. W., Field, C. J., & Fairey, 
A. S. (2003). Randomized controlled trial of exercise training in 
postmenopausal breast cancer survivors: cardiopulmonary and quality of 
life outcomes. J Clin Oncol, 21(9), 1660-1668. 
Courneya, K. S., Segal, R. J., Mackey, J. R., Gelmon, K., Reid, R. D., 
Friedenreich, C. M., Ladha, A. B., Proulx, C., Vallance, J. K., Lane, K., 
Yasui, Y., & McKenzie, D. C. (2007). Effects of aerobic and resistance 
exercise in breast cancer patients receiving adjuvant chemotherapy: a 
multicenter randomized controlled trial. J Clin Oncol, 25(28), 4396-4404. 
De Backer, I. C., Schep, G., Backx, F. J., Vreugdenhil, G., & Kuipers, H. (2009). 
Resistance training in cancer survivors: a systematic review. Int J Sports 
Med, 30(10), 703-712. 
 99 
De Backer, I. C., Schep, G., Hoogeveen, A., Vreugdenhil, G., Kester, A. D., & 
van Breda, E. (2007). Exercise testing and training in a cancer 
rehabilitation program: the advantage of the steep ramp test. Arch Phys 
Med Rehabil, 88(5), 610-616. 
De Backer, I. C., Van Breda, E., Vreugdenhil, A., Nijziel, M. R., Kester, A. D., & 
Schep, G. (2007). High-intensity strength training improves quality of life 
in cancer survivors. Acta Oncol, 46(8), 1143-1151. 
Demark-Wahnefried, W., Campbell, K. L., & Hayes, S. C. (2012). Weight 
management and its role in breast cancer rehabilitation. Cancer, 118(8 
Suppl), 2277-2287. 
Demark-Wahnefried, W., Peterson, B., McBride, C., Lipkus, I., & Clipp, E. 
(2000). Current health behaviors and readiness to pursue life-style 
changes among men and women diagnosed with early stage prostate 
and breast carcinomas. Cancer, 88(3), 674-684. 
Devoogdt, N., Van Kampen, M., Geraerts, I., Coremans, T., Fieuws, S., Lefevre, 
J., Philippaerts, R., Truijen, S., Neven, P., & Christiaens, M. R. (2010). 
Physical activity levels after treatment for breast cancer: one-year follow-
up. Breast Cancer Res Treat, 123(2), 417-425. 
Dimeo, F. (2000). Exercise for cancer patients: a new challenge in sports 
medicine. West J Med, 173(4), 272-273. 
Dimeo, F., Fetscher, S., Lange, W., Mertelsmann, R., & Keul, J. (1997). Effects 
of aerobic exercise on the physical performance and incidence of 
treatment-related complications after high-dose chemotherapy. Blood, 
90(9), 3390-3394. 
Dimeo, F., Schwartz, S., Fietz, T., Wanjura, T., Boning, D., & Thiel, E. (2003). 
Effects of endurance training on the physical performance of patients 
with hematological malignancies during chemotherapy. Support Care 
Cancer, 11(10), 623-628. 
Dimeo, F., Stieglitz, R. D., Novelli-Fischer, U., Fetscher, S., Mertelsmann, R., & 
Keul, J. (1997). Correlation between physical performance and fatigue in 
cancer patients. Ann Oncol, 8(12), 1251-1255. 
 100 
Dimeo, F. C. (2001). Effects of exercise on cancer-related fatigue. Cancer, 92(6 
Suppl), 1689-1693. 
Dimeo, F. C., Stieglitz, R. D., Novelli-Fischer, U., Fetscher, S., & Keul, J. 
(1999). Effects of physical activity on the fatigue and psychologic status 
of cancer patients during chemotherapy. Cancer, 85(10), 2273-2277. 
Dowlati, A., R'Zik, S., Fillet, G., & Beguin, Y. (1997). Anaemia of lung cancer is 
due to impaired erythroid marrow response to erythropoietin stimulation 
as well as relative inadequacy of erythropoietin production. Br J 
Haematol, 97(2), 297-299. 
Drolet, M., Maunsell, E., Mondor, M., Brisson, C., Brisson, J., Masse, B., & 
Deschenes, L. (2005). Work absence after breast cancer diagnosis: a 
population-based study. CMAJ, 173(7), 765-771. 
Drouin, J. S. (2004). Exercise in older individuals with cancer. Topics in 
Geriatric Rehabilitation, 20(2), 81-97. 
Drouin, J. S., Young, T. J., Beeler, J., Byrne, K., Birk, T. J., Hryniuk, W. M., & 
Hryniuk, L. E. (2006). Random control clinical trial on the effects of 
aerobic exercise training on erythrocyte levels during radiation treatment 
for breast cancer. Cancer, 107(10), 2490-2495. 
Eheman, C., Henley, S. J., Ballard-Barbash, R., Jacobs, E. J., Schymura, M. J., 
Noone, A. M., Pan, L., Anderson, R. N., Fulton, J. E., Kohler, B. A., 
Jemal, A., Ward, E., Plescia, M., Ries, L. A., & Edwards, B. K. (2012). 
Annual Report to the Nation on the status of cancer, 1975-2008, 
featuring cancers associated with excess weight and lack of sufficient 
physical activity. Cancer, 118(9), 2338-2366. 
Erickson, J. M. (2004). Fatigue in adolescents with cancer: a review of the 
literature. Clin J Oncol Nurs, 8(2), 139-145. 
Fayers, P. M. (2001). Interpreting quality of life data: population-based 
reference data for the EORTC QLQ-C30. Eur J Cancer, 37(11), 1331-
1334. 
Ferrer, R. A., Huedo-Medina, T. B., Johnson, B. T., Ryan, S., & Pescatello, L. S. 
(2011). Exercise interventions for cancer survivors: a meta-analysis of 
quality of life outcomes. Ann Behav Med, 41(1), 32-47. 
 101 
Friedenreich, C. M. (2001). Physical activity and cancer prevention: from 
observational to intervention research. Cancer Epidemiol Biomarkers 
Prev, 10(4), 287-301. 
Galvao, D. A., & Newton, R. U. (2005). Review of exercise intervention studies 
in cancer patients. J Clin Oncol, 23(4), 899-909. 
Garber, C. E., Blissmer, B., Deschenes, M. R., Franklin, B. A., Lamonte, M. J., 
Lee, I. M., Nieman, D. C., & Swain, D. P. (2011). American College of 
Sports Medicine position stand. Quantity and quality of exercise for 
developing and maintaining cardiorespiratory, musculoskeletal, and 
neuromotor fitness in apparently healthy adults: guidance for prescribing 
exercise. Med Sci Sports Exerc, 43(7), 1334-1359. 
Gartner, R., Jensen, M. B., Nielsen, J., Ewertz, M., Kroman, N., & Kehlet, H. 
(2009). Prevalence of and factors associated with persistent pain 
following breast cancer surgery. JAMA, 302(18), 1985-1992. 
Geinitz, H., Zimmermann, F. B., Stoll, P., Thamm, R., Kaffenberger, W., Ansorg, 
K., Keller, M., Busch, R., van Beuningen, D., & Molls, M. (2001). Fatigue, 
serum cytokine levels, and blood cell counts during radiotherapy of 
patients with breast cancer. Int J Radiat Oncol Biol Phys, 51(3), 691-698. 
Gianni, L., Dombernowsky, P., Sledge, G., Martin, M., Amadori, D., Arbuck, S. 
G., Ravdin, P., Brown, M., Messina, M., Tuck, D., Weil, C., & Winograd, 
B. (2001). Cardiac function following combination therapy with paclitaxel 
and doxorubicin: an analysis of 657 women with advanced breast 
cancer. Ann Oncol, 12(8), 1067-1073. 
Groopman, J. E., & Itri, L. M. (1999). Chemotherapy-induced anemia in adults: 
incidence and treatment. J Natl Cancer Inst, 91(19), 1616-1634. 
Guise, T. A. (2006). Bone loss and fracture risk associated with cancer therapy. 
Oncologist, 11(10), 1121-1131. 
Harvie, M. N., Campbell, I. T., Baildam, A., & Howell, A. (2004). Energy balance 
in early breast cancer patients receiving adjuvant chemotherapy. Breast 
Cancer Res Treat, 83(3), 201-210. 
 102 
Haykowsky, M. J., Mackey, J. R., Thompson, R. B., Jones, L. W., & Paterson, 
D. I. (2009). Adjuvant trastuzumab induces ventricular remodeling 
despite aerobic exercise training. Clin Cancer Res, 15(15), 4963-4967. 
Hayward, R., Ruangthai, R., Schneider, C. M., Hyslop, R. M., Strange, R., & 
Westerlind, K. C. (2004). Training enhances vascular relaxation after 
chemotherapy-induced vasoconstriction. Med Sci Sports Exerc, 36(3), 
428-434. 
Headley, J. A., Theriault, R. L., LeBlanc, A. D., Vassilopoulou-Sellin, R., & 
Hortobagyi, G. N. (1998). Pilot study of bone mineral density in breast 
cancer patients treated with adjuvant chemotherapy. Cancer Invest, 
16(1), 6-11. 
Herrero, F., San Juan, A. F., Fleck, S. J., Balmer, J., Perez, M., Canete, S., 
Earnest, C. P., Foster, C., & Lucia, A. (2006). Combined aerobic and 
resistance training in breast cancer survivors: A randomized, controlled 
pilot trial. Int J Sports Med, 27(7), 573-580. 
Herrero, F., San Juan, A. F., Fleck, S. J., Foster, C., & Lucia, A. (2007). Effects 
of detraining on the functional capacity of previously trained breast 
cancer survivors. Int J Sports Med, 28(3), 257-264. 
Holmes, M. D., Chen, W. Y., Feskanich, D., Kroenke, C. H., & Colditz, G. A. 
(2005). Physical activity and survival after breast cancer diagnosis. 
JAMA, 293(20), 2479-2486. 
Hoving, J. L., Broekhuizen, M. L., & Frings-Dresen, M. H. (2009). Return to 
work of breast cancer survivors: a systematic review of intervention 
studies. BMC Cancer, 9, 117. 
Ingram, C., & Visovsky, C. (2007). Exercise intervention to modify physiologic 
risk factors in cancer survivors. Semin Oncol Nurs, 23(4), 275-284. 
Inui, A. (2002). Cancer anorexia-cachexia syndrome: current issues in research 
and management. CA Cancer J Clin, 52(2), 72-91. 
Itri, L. M. (2000). Optimal hemoglobin levels for cancer patients. Semin Oncol, 
27(2 Suppl 4), 12-15; discussion 16-17. 
Jemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., & Forman, D. (2011). 
Global cancer statistics. CA Cancer J Clin, 61(2), 69-90. 
 103 
Karvinen, K. H., Raedeke, T. D., Arastu, H., & Allison, R. R. (2011). Exercise 
programming and counseling preferences of breast cancer survivors 
during or after radiation therapy. Oncol Nurs Forum, 38(5), E326-334. 
Kilgour, R. D., Vigano, A., Trutschnigg, B., Hornby, L., Lucar, E., Bacon, S. L., & 
Morais, J. A. (2010). Cancer-related fatigue: the impact of skeletal 
muscle mass and strength in patients with advanced cancer. J Cachexia 
Sarcopenia Muscle, 1(2), 177-185. 
Klauber-DeMore, N. (2005). Tumor biology of breast cancer in young women. 
Breast Dis, 23, 9-15. 
Knobel, H., Loge, J. H., Brenne, E., Fayers, P., Hjermstad, M. J., & Kaasa, S. 
(2003). The validity of EORTC QLQ-C30 fatigue scale in advanced 
cancer patients and cancer survivors. Palliat Med, 17(8), 664-672. 
Knobf, M. T., Insogna, K., DiPietro, L., Fennie, C., & Thompson, A. S. (2008). 
An aerobic weight-loaded pilot exercise intervention for breast cancer 
survivors: bone remodeling and body composition outcomes. Biol Res 
Nurs, 10(1), 34-43. 
Knutsen, L., Quist, M., Midtgaard, J., Rorth, M., & Adamsen, L. (2006). 
Maximum physical capacity testing in cancer patients undergoing 
chemotherapy: qualitative findings from an exercise program. Scand J 
Med Sci Sports, 16(6), 403-411. 
Kolden, G. G., Strauman, T. J., Ward, A., Kuta, J., Woods, T. E., Schneider, K. 
L., Heerey, E., Sanborn, L., Burt, C., Millbrandt, L., Kalin, N. H., Stewart, 
J. A., & Mullen, B. (2002). A pilot study of group exercise training (GET) 
for women with primary breast cancer: feasibility and health benefits. 
Psychooncology, 11(5), 447-456. 
Kosmidis, P., & Krzakowski, M. (2005). Anemia profiles in patients with lung 
cancer: what have we learned from the European Cancer Anaemia 
Survey (ECAS)? Lung Cancer, 50(3), 401-412. 
Langer, C. J., Choy, H., Glaspy, J. A., & Colowick, A. (2002). Standards of care 
for anemia management in oncology: focus on lung carcinoma. Cancer, 
95(3), 613-623. 
 104 
Langer, C. J., Leighton, J. C., Comis, R. L., O'Dwyer, P. J., McAleer, C. A., 
Bonjo, C. A., Engstrom, P. F., Litwin, S., Johnson, S., & Ozols, R. F. 
(1995). Paclitaxel by 24- or 1-hour infusion n combination with 
carboplatin in advanced non-small cell lung cancer: the Fox Chase 
Cancer Center experience. Semin Oncol, 22(4 Suppl 9), 18-29. 
Laviolette, L., Bourbeau, J., Bernard, S., Lacasse, Y., Pepin, V., Breton, M. J., 
Baltzan, M., Rouleau, M., & Maltais, F. (2008). Assessing the impact of 
pulmonary rehabilitation on functional status in COPD. Thorax, 63(2), 
115-121. 
Lee, S. G., Jee, Y. G., Chung, H. C., Kim, S. B., Ro, J., Im, Y. H., Im, S. A., & 
Seo, J. H. (2009). Cost-effectiveness analysis of adjuvant therapy for 
node positive breast cancer in Korea: docetaxel, doxorubicin and 
cyclophosphamide (TAC) versus fluorouracil, doxorubicin and 
cyclophosphamide (FAC). Breast Cancer Res Treat, 114(3), 589-595. 
Levine, B. D., Zuckerman, J. H., & Pawelczyk, J. A. (1997). Cardiac atrophy 
after bed-rest deconditioning: a nonneural mechanism for orthostatic 
intolerance. Circulation, 96(2), 517-525. 
Loprinzi, P. D., & Cardinal, B. J. (2012). Effects of physical activity on common 
side effects of breast cancer treatment. Breast Cancer, 19(1), 4-10. 
Lucia, A., Earnest, C., & Perez, M. (2003). Cancer-related fatigue: can exercise 
physiology assist oncologists? Lancet Oncol, 4(10), 616-625. 
Ludwig, H., & Strasser, K. (2001). Symptomatology of anemia. Semin Oncol, 
28(2 Suppl 8), 7-14. 
Ludwig, H., Van Belle, S., Barrett-Lee, P., Birgegard, G., Bokemeyer, C., 
Gascon, P., Kosmidis, P., Krzakowski, M., Nortier, J., Olmi, P., 
Schneider, M., & Schrijvers, D. (2004). The European Cancer Anaemia 
Survey (ECAS): a large, multinational, prospective survey defining the 
prevalence, incidence, and treatment of anaemia in cancer patients. Eur 
J Cancer, 40(15), 2293-2306. 
MacVicar, M. G., Winningham, M. L., & Nickel, J. L. (1989). Effects of aerobic 
interval training on cancer patients' functional capacity. Nurs Res, 38(6), 
348-351. 
 105 
Makari-Judson, G., Judson, C. H., & Mertens, W. C. (2007). Longitudinal 
patterns of weight gain after breast cancer diagnosis: observations 
beyond the first year. Breast J, 13(3), 258-265. 
Martin, M., Pienkowski, T., Mackey, J., Pawlicki, M., Guastalla, J. P., Weaver, 
C., Tomiak, E., Al-Tweigeri, T., Chap, L., Juhos, E., Guevin, R., Howell, 
A., Fornander, T., Hainsworth, J., Coleman, R., Vinholes, J., Modiano, 
M., Pinter, T., Tang, S. C., Colwell, B., Prady, C., Provencher, L., Walde, 
D., Rodriguez-Lescure, A., Hugh, J., Loret, C., Rupin, M., Blitz, S., 
Jacobs, P., Murawsky, M., Riva, A., & Vogel, C. (2005). Adjuvant 
docetaxel for node-positive breast cancer. N Engl J Med, 352(22), 2302-
2313. 
McKenzie, D. C., & Kalda, A. L. (2003). Effect of upper extremity exercise on 
secondary lymphedema in breast cancer patients: a pilot study. J Clin 
Oncol, 21(3), 463-466. 
Mock, V., Dow, K. H., Meares, C. J., Grimm, P. M., Dienemann, J. A., Haisfield-
Wolfe, M. E., Quitasol, W., Mitchell, S., Chakravarthy, A., & Gage, I. 
(1997). Effects of exercise on fatigue, physical functioning, and emotional 
distress during radiation therapy for breast cancer. Oncol Nurs Forum, 
24(6), 991-1000. 
Mock, V., Frangakis, C., Davidson, N. E., Ropka, M. E., Pickett, M., 
Poniatowski, B., Stewart, K. J., Cameron, L., Zawacki, K., Podewils, L. J., 
Cohen, G., & McCorkle, R. (2005). Exercise manages fatigue during 
breast cancer treatment: a randomized controlled trial. Psychooncology, 
14(6), 464-477. 
Mock, V., Pickett, M., Ropka, M. E., Muscari Lin, E., Stewart, K. J., Rhodes, V. 
A., McDaniel, R., Grimm, P. M., Krumm, S., & McCorkle, R. (2001). 
Fatigue and quality of life outcomes of exercise during cancer treatment. 
Cancer Pract, 9(3), 119-127. 
Monga, U., Jaweed, M., Kerrigan, A. J., Lawhon, L., Johnson, J., Vallbona, C., 
& Monga, T. N. (1997). Neuromuscular fatigue in prostate cancer 
patients undergoing radiation therapy. Arch Phys Med Rehabil, 78(9), 
961-966. 
 106 
Mustian, K. M., Peppone, L., Darling, T. V., Palesh, O., Heckler, C. E., & 
Morrow, G. R. (2009). A 4-week home-based aerobic and resistance 
exercise program during radiation therapy: a pilot randomized clinical 
trial. J Support Oncol, 7(5), 158-167. 
Myers, J., Prakash, M., Froelicher, V., Do, D., Partington, S., & Atwood, J. E. 
(2002). Exercise capacity and mortality among men referred for exercise 
testing. N Engl J Med, 346(11), 793-801. 
Naumann, F., Munro, A., Martin, E., Magrani, P., Buchan, J., Smith, C., Piggott, 
B., & Philpott, M. (2012). An individual-based versus group-based 
exercise and counselling intervention for improving quality of life in breast 
cancer survivors. A feasibility and efficacy study. Psychooncology, 
21(10), 1136-1139. 
Nikander, R., Sievanen, H., Ojala, K., Kellokumpu-Lehtinen, P., Palva, T., 
Blomqvist, C., Luoto, R., & Saarto, T. (2012). Effect of exercise on bone 
structural traits, physical performance and body composition in breast 
cancer patients - A 12-month RCT. J Musculoskelet Neuronal Interact, 
12(3), 127-135. 
Nikander, R., Sievanen, H., Ojala, K., Oivanen, T., Kellokumpu-Lehtinen, P. L., 
& Saarto, T. (2007). Effect of a vigorous aerobic regimen on physical 
performance in breast cancer patients - a randomized controlled pilot 
trial. Acta Oncol, 46(2), 181-186. 
Noakes, T. D. (2000). Physiological models to understand exercise fatigue and 
the adaptations that predict or enhance athletic performance. Scand J 
Med Sci Sports, 10(3), 123-145. 
Ohira, T., Schmitz, K. H., Ahmed, R. L., & Yee, D. (2006). Effects of weight 
training on quality of life in recent breast cancer survivors: the Weight 
Training for Breast Cancer Survivors (WTBS) study. Cancer, 106(9), 
2076-2083. 
Oldervoll, L. M., Kaasa, S., Knobel, H., & Loge, J. H. (2003). Exercise reduces 
fatigue in chronic fatigued Hodgkins disease survivors--results from a 
pilot study. Eur J Cancer, 39(1), 57-63. 
 107 
Ong, K. C., Chong, W. F., Soh, C., & Earnest, A. (2004). Comparison of 
different exercise tests in assessing outcomes of pulmonary 
rehabilitation. Respir Care, 49(12), 1498-1503. 
Pedersen, B. K., & Saltin, B. (2006). Evidence for prescribing exercise as 
therapy in chronic disease. Scand J Med Sci Sports, 16 Suppl 1, 3-63. 
Perhonen, M. A., Franco, F., Lane, L. D., Buckey, J. C., Blomqvist, C. G., 
Zerwekh, J. E., Peshock, R. M., Weatherall, P. T., & Levine, B. D. (2001). 
Cardiac atrophy after bed rest and spaceflight. J Appl Physiol, 91(2), 
645-653. 
Peteet, J. R. (2000). Cancer and the meaning of work. Gen Hosp Psychiatry, 
22(3), 200-205. 
Protani, M., Coory, M., & Martin, J. H. (2010). Effect of obesity on survival of 
women with breast cancer: systematic review and meta-analysis. Breast 
Cancer Res Treat, 123(3), 627-635. 
Quist, M., Rorth, M., Zacho, M., Andersen, C., Moeller, T., Midtgaard, J., & 
Adamsen, L. (2006). High-intensity resistance and cardiovascular 
training improve physical capacity in cancer patients undergoing 
chemotherapy. Scand J Med Sci Sports, 16(5), 349-357. 
Rief, W., Bardwell, W. A., Dimsdale, J. E., Natarajan, L., Flatt, S. W., & Pierce, 
J. P. (2011). Long-term course of pain in breast cancer survivors: a 4-
year longitudinal study. Breast Cancer Res Treat, 130(2), 579-586. 
Rizzo, J. D., Lichtin, A. E., Woolf, S. H., Seidenfeld, J., Bennett, C. L., Cella, D., 
Djulbegovic, B., Goode, M. J., Jakubowski, A. A., Lee, S. J., Miller, C. B., 
Rarick, M. U., Regan, D. H., Browman, G. P., & Gordon, M. S. (2002). 
Use of epoetin in patients with cancer: evidence-based clinical practice 
guidelines of the American Society of Clinical Oncology and the 
American Society of Hematology. J Clin Oncol, 20(19), 4083-4107. 
Rock, C. L., & Demark-Wahnefried, W. (2002). Nutrition and survival after the 
diagnosis of breast cancer: a review of the evidence. J Clin Oncol, 
20(15), 3302-3316. 
Rundle, A. (2005). Molecular epidemiology of physical activity and cancer. 
Cancer Epidemiol Biomarkers Prev, 14(1), 227-236. 
 108 
Ryan, J. L., Carroll, J. K., Ryan, E. P., Mustian, K. M., Fiscella, K., & Morrow, G. 
R. (2007). Mechanisms of cancer-related fatigue. Oncologist, 12 Suppl 1, 
22-34. 
Saarto, T., Sievanen, H., Kellokumpu-Lehtinen, P., Nikander, R., Vehmanen, L., 
Huovinen, R., Kautiainen, H., Jarvenpaa, S., Penttinen, H. M., Utriainen, 
M., Jaaskelainen, A. S., Elme, A., Ruohola, J., Palva, T., Vertio, H., 
Rautalahti, M., Fogelholm, M., Luoto, R., & Blomqvist, C. (2012). Effect 
of supervised and home exercise training on bone mineral density 
among breast cancer patients. A 12-month randomised controlled trial. 
Osteoporos Int, 23(5), 1601-1612. 
Satariano, W. A., & DeLorenze, G. N. (1996). The likelihood of returning to work 
after breast cancer. Public Health Rep, 111(3), 236-241. 
Schmitz, K. H., Ahmed, R. L., Troxel, A., Cheville, A., Smith, R., Lewis-Grant, 
L., Bryan, C. J., Williams-Smith, C. T., & Greene, Q. P. (2009). Weight 
lifting in women with breast-cancer-related lymphedema. N Engl J Med, 
361(7), 664-673. 
Schmitz, K. H., Courneya, K. S., Matthews, C., Demark-Wahnefried, W., 
Galvao, D. A., Pinto, B. M., Irwin, M. L., Wolin, K. Y., Segal, R. J., Lucia, 
A., Schneider, C. M., von Gruenigen, V. E., & Schwartz, A. L. (2010). 
American College of Sports Medicine roundtable on exercise guidelines 
for cancer survivors. Med Sci Sports Exerc, 42(7), 1409-1426. 
Schneider, C. M., Hsieh, C. C., Sprod, L. K., Carter, S. D., & Hayward, R. 
(2007). Effects of supervised exercise training on cardiopulmonary 
function and fatigue in breast cancer survivors during and after 
treatment. Cancer, 110(4), 918-925. 
Schwartz, A. L., Mori, M., Gao, R., Nail, L. M., & King, M. E. (2001). Exercise 
reduces daily fatigue in women with breast cancer receiving 
chemotherapy. Med Sci Sports Exerc, 33(5), 718-723. 
Schwartz, A. L., Winters-Stone, K., & Gallucci, B. (2007). Exercise effects on 
bone mineral density in women with breast cancer receiving adjuvant 
chemotherapy. Oncol Nurs Forum, 34(3), 627-633. 
 109 
Segal, R., Evans, W., Johnson, D., Smith, J., Colletta, S., Gayton, J., Woodard, 
S., Wells, G., & Reid, R. (2001). Structured exercise improves physical 
functioning in women with stages I and II breast cancer: results of a 
randomized controlled trial. J Clin Oncol, 19(3), 657-665. 
Segal, R. J., Reid, R. D., Courneya, K. S., Malone, S. C., Parliament, M. B., 
Scott, C. G., Venner, P. M., Quinney, H. A., Jones, L. W., D'Angelo, M. 
E., & Wells, G. A. (2003). Resistance exercise in men receiving 
androgen deprivation therapy for prostate cancer. J Clin Oncol, 21(9), 
1653-1659. 
Sestak, I., Harvie, M., Howell, A., Forbes, J. F., Dowsett, M., & Cuzick, J. 
(2012). Weight change associated with anastrozole and tamoxifen 
treatment in postmenopausal women with or at high risk of developing 
breast cancer. Breast Cancer Res Treat, 134(2), 727-734. 
Smets, E. M., Visser, M. R., Willems-Groot, A. F., Garssen, B., Oldenburger, F., 
van Tienhoven, G., & de Haes, J. C. (1998). Fatigue and radiotherapy: 
(A) experience in patients undergoing treatment. Br J Cancer, 78(7), 899-
906. 
Smets, E. M., Visser, M. R., Willems-Groot, A. F., Garssen, B., Schuster-
Uitterhoeve, A. L., & de Haes, J. C. (1998). Fatigue and radiotherapy: (B) 
experience in patients 9 months following treatment. Br J Cancer, 78(7), 
907-912. 
Spence, R. R., Heesch, K. C., & Brown, W. J. (2010). Exercise and cancer 
rehabilitation: a systematic review. Cancer Treat Rev, 36(2), 185-194. 
Spina, R. J., Rashid, S., Davila-Roman, V. G., & Ehsani, A. A. (2000). 
Adaptations in beta-adrenergic cardiovascular responses to training in 
older women. J Appl Physiol, 89(6), 2300-2305. 
Sprod, L. K., Hsieh, C. C., Hayward, R., & Schneider, C. M. (2010). Three 
versus six months of exercise training in breast cancer survivors. Breast 
Cancer Res Treat, 121(2), 413-419. 
Stasi, R., Abriani, L., Beccaglia, P., Terzoli, E., & Amadori, S. (2003). Cancer-
related fatigue: evolving concepts in evaluation and treatment. Cancer, 
98(9), 1786-1801. 
 110 
Stone, P., Richards, M., A'Hern, R., & Hardy, J. (2000). A study to investigate 
the prevalence, severity and correlates of fatigue among patients with 
cancer in comparison with a control group of volunteers without cancer. 
Ann Oncol, 11(5), 561-567. 
Stone, P., Richards, M., & Hardy, J. (1998). Fatigue in patients with cancer. Eur 
J Cancer, 34(11), 1670-1676. 
Straus, D. J., Testa, M. A., Sarokhan, B. J., Czuczman, M. S., Tulpule, A., 
Turner, R. R., & Riggs, S. A. (2006). Quality-of-life and health benefits of 
early treatment of mild anemia: a randomized trial of epoetin alfa in 
patients receiving chemotherapy for hematologic malignancies. Cancer, 
107(8), 1909-1917. 
Stricker, C. T., Drake, D., Hoyer, K. A., & Mock, V. (2004). Evidence-based 
practice for fatigue management in adults with cancer: exercise as an 
intervention. Oncol Nurs Forum, 31(5), 963-976. 
Swenson, K. K., Nissen, M. J., Leach, J. W., & Post-White, J. (2009). Case-
control study to evaluate predictors of lymphedema after breast cancer 
surgery. Oncol Nurs Forum, 36(2), 185-193. 
Thorsen, L., Skovlund, E., Stromme, S. B., Hornslien, K., Dahl, A. A., & Fossa, 
S. D. (2005). Effectiveness of physical activity on cardiorespiratory 
fitness and health-related quality of life in young and middle-aged cancer 
patients shortly after chemotherapy. J Clin Oncol, 23(10), 2378-2388. 
Velthuis, M. J., May, A. M., Koppejan-Rensenbrink, R. A., Gijsen, B. C., van 
Breda, E., de Wit, G. A., Schroder, C. D., Monninkhof, E. M., Lindeman, 
E., van der Wall, E., & Peeters, P. H. (2010). Physical Activity during 
Cancer Treatment (PACT) Study: design of a randomised clinical trial. 
BMC Cancer, 10, 272. 
Waltman, N. L., Twiss, J. J., Ott, C. D., Gross, G. J., Lindsey, A. M., Moore, T. 
E., & Berg, K. (2003). Testing an intervention for preventing osteoporosis 
in postmenopausal breast cancer survivors. J Nurs Scholarsh, 35(4), 
333-338. 
Watson, T., & Mock, V. (2004). Exercise as an intervention for cancer-related 
fatigue. Phys Ther, 84(8), 736-743. 
 111 
Winkelman, C. (2004). Inactivity and inflammation: selected cytokines as 
biologic mediators in muscle dysfunction during critical illness. AACN 
Clin Issues, 15(1), 74-82. 
Winningham, M. L. (2001). Strategies for managing cancer-related fatigue 
syndrome: a rehabilitation approach. Cancer, 92(4 Suppl), 988-997. 
Winningham, M. L., MacVicar, M. G., Bondoc, M., Anderson, J. I., & Minton, J. 
P. (1989). Effect of aerobic exercise on body weight and composition in 
patients with breast cancer on adjuvant chemotherapy. Oncol Nurs 
Forum, 16(5), 683-689. 
Winters-Stone, K. M., Bennett, J. A., Nail, L., & Schwartz, A. (2008). Strength, 
physical activity, and age predict fatigue in older breast cancer survivors. 
Oncol Nurs Forum, 35(5), 815-821. 
Wolin, K. Y., Schwartz, A. L., Matthews, C. E., Courneya, K. S., & Schmitz, K. 
H. (2012). Implementing the exercise guidelines for cancer survivors. J 
Support Oncol, 10(5), 171-177. 
Zbreski, M. G., Helwig, B. G., Mitchell, K. E., Musch, T. I., Weiss, M. L., & 
McAllister, R. M. (2006). Effects of cyclosporine-A on rat soleus muscle 
fiber size and phenotype. Med Sci Sports Exerc, 38(5), 833-839. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 112 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 113 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
9. Attachments 
 
  
Termo de Consentimento 
Programa de Exercício em Mulheres com Cancro da Mama 
 
 
No âmbito do Doutoramento em Ciências do Desporto na Faculdade de Desporto da 
Universidade do Porto, está a decorrer uma investigação sobre o efeito do exercício físico na 
qualidade de vida em Mulheres com cancro da mama. 
O conhecimento das alterações funcionais e estruturais dos pacientes com cancro durante e 
após o tratamento, torna-se fundamental para o desenvolvimento de programas de 
prevenção da fadiga relacionada com o cancro.  
Este trabalho tem como objectivo geral analisar e descrever o efeito individualizado do treino 
e exercício, com finalidade terapêutica, nas alterações da função aeróbia e muscular, durante 
e após o período de tratamento em pacientes com cancro.  
Para se conseguir executar esta fase do trabalho é necessário avaliar a qualidade de vida, a 
função muscular e aeróbia através da avaliação em ciclo ergómetro com espirometria. 
Para o efeito, apela-se à colaboração de pessoas para integrarem a amostra do 
estudo, pelo que, se solicitam algumas informações e obtenção de consentimento 
informado. 
 
 
Nome  _________________________________________________  Idade _________ 
 
Data de Nascimento _________________            B.I. __________________ 
 
Declaro, por meio deste termo, que concordo em participar na pesquisa de campo referente 
a este trabalho sobre “O efeito do exercício em pacientes com cancro”, desenvolvido pelo 
aluno de Doutoramento, Eduardo Oliveira, sob orientação do Prof. Doutor José Soares e 
colaboração da Prof. Doutora Maria João Cardoso, Presidente do Centro MamaHelp.  
Fui informada da garantia de anonimato, de ser submetido(a) a um inquérito sobre 
Qualidade de Vida através de um questionário bem como ser submetido a um inquérito sobre 
a História Clínica e Estilo de Vida 
Declaro que fui informada que serei pesado numa balança de bio-impedância para 
determinar a composição coporal. A respectiva medição terá de ser realizada sem sapatos e 
sem meias. 
Declaro ter sido informada sobre a medição da frequência cardíaca de repouso e da 
variabilidade da frequência cardíaca. O protocolo desta medição consiste em avaliar a 
frequência cardíaca em decúbito dorsal durante dez minutos.  
Declaro ter sido informada sobre o protocolo da medição da força de preensão da mão e 
medição da força dos membros inferiores nomeadamente do quadricipite. A medição da força 
é realizada pela capacidade de produzir força com máxima intensidade durante três 
segundos com recurso a um dinamómetro portátil.  
Declaro que fui informada sobre a medição da aptidão cárdio-respiratória que é realizada 
através de uma prova de esforço numa bicicleta estática com um protocolo de exercício que 
aumenta progressivamente a intensidade. Para esta avaliação é necessário colocar uma 
 máscara que envolve a boca e o nariz com o objectivo de se avaliar os gases inspirados e 
expirados. Para além disso será colocado um aparelho no peito para registar a frequência 
cardiaca durante a prova de esforço e monitorizar a intensidade de exercício.  
Declaro que fui informada que os custos de deslocação MamaHelp serão por mim assumidos 
(nome) ____________________________. 
Declaro que fui esclarecida que caso haja necessidade de realizar um hemograma, os custos 
serão suportados pelo projecto que está a decorrer.  
 
Declaro que fui informada que o protocolo de exercício terá a duração de 12 semanas (3 
meses) com uma frequência de 2 vezes por semana. Cada sessão de exercício terá a 
duração de 45 minutos. O programa de exercício poderá ser realizado de duas formas. A 
primeira possibilidade é realizar o exercício físico no MamaHelp com ajuda de profissionais 
especializados. A segunda possibilidade é realizar o programa de exercício no domicílio. 
Neste caso, os exercícios serão explicados previamente no MamaHelp. O protocolo de 
exercício será constituído por exercícios de reforço muscular. O meio utilizado para se 
melhorar a funcionalidade muscular será através do recurso a elásticos. Este material será 
fornecido sendo os custos suportados pelo respectivo projecto.   
Declaro que fui esclarecida que o protocolo de avaliação terá dois momentos de avaliação 
com uma distância temporal de 12 semanas entre eles. O primeiro momento de avaliação 
corresponde à avaliação inicial e segunda e última avaliação corresponde ao términus do 
programa de exercício (semana 12). 
 
Afirmo que aceito participar por minha própria vontade, sem receber qualquer incentivo 
financeiro e com a finalidade exclusiva de colaborar para o sucesso deste trabalho.  
 
 
____________________ , ____ de Outubro de 2011 
 
 
____________________________________ 
(Assinatura) 
 
 
Muito obrigado pela colaboração! 
 
História clínica  
Schneider, C.; Dennehy, C.; Carter, S. (2003) Exercise and Cancer Recovery. (Champaign, IL: Human 
Kinetics). Usado com permissão do MamaHelp 
 
Nome ______________________________________  Data ________________ 
Morada __________________________________________________________ 
Código Postal ________-______  Localidade _____________________________ 
Telefone ____________________ Data Nascimento ___________  Idade _____ 
Email ___________________________________________________________ 
 
 
 
Tipo de cancro:_______________________ Data do Diagnóstico:___________ 
Localização Específica:_____________________  (p. ex. Lado dir/esq do peito) 
Cirurgia: ___ Sim   ___ Não       Data da cirurgia: ________________________ 
Tipo de Cirurgia: __________________________________________________  
Outras Cirurgias: __________________________________________________ 
Sintomas: ________________________________________________________ 
_______________________ (sintomas que teve que originaram o diagnóstico de 
cancro: fadiga, náuseas, etc.) 
Tratamento pós cirurgia (quimioterapia, radioterapia): _____________________ 
Duração do tratamento: _____________________________________________ 
Data do último tratamento: __________________________________________ 
Actualmente realiza quimioterapia? ___sim   ___ não 
              Se sim, qual a data último tratamento? _________________________ 
Actualmente realiza radioterapia? ___ sim  ___ não 
               Se sim, qual a data último tratamento? _________________________ 
Tomas algum tipo de medicação? ___sim   ___ não 
               Se sim qual? ______________________________________________ 
_________________________________________________________________ 
 
 
 
Estilo de Vida / Avaliação da Actividade Física  
Schneider, C.; Dennehy, C.; Carter, S. (2003) Exercise and Cancer Recovery. (Champaign, IL: Human 
Kinetics). Usado com permissão do MamaHelp  
 
 
Nome: ________________________________________  Data: _____________ 
 
Tabagismo 
1. Alguma vez já fumou? ____________________________________________ 
2. Fuma actualmente? ____   Quantidade por dia/semana __________________ 
3. Com que idade começou a fumar? ___________________________________ 
4. Com que idade deixou de fumar? ____________________________________ 
 
Ingestão de bebidas alcoólicas 
1. No último mês, quantos dias por semana ingeriu bebidas alcoólicas?  _______ 
2. No último mês, qual a quantidade de ingerida apenas numa ocasião? _______ 
 
Sono 
1. Durante a última semana, qual foi a média de horas de sono durante a semana 
(segunda a sexta feira)? _____________________________________________ 
2. Qual foi a média de horas de sono aos fins de semana (Sábado e Domingo)? _ 
________________________________________________________________ 
 
Exercício  
1. Realiza exercício de uma forma regular? ______________________________ 
2. Que tipo de exercícios realiza de uma forma regular? ____________________ 
3. Quantos dias por semana realiza exercício de uma forma regular? __________ 
4. Qual o tempo dispendido numa única sessão de exercício (minutos)? ________ 
5. Considera o seu exercício de baixa, moderada ou elavada intensidade? ______ 
6. Assinale o seu tipo de ocupação profissional: 
       _____  Inactivo(a) (p.ex. trabalho numa secretária) 
       _____  Trabalho ligeiro (p.ex. trabalhos em casa, jardinagem) 
       _____  Trabalho intenso (p.ex. carregar objectos pesados) 
7. Que tipo de actividade física o(a) motiva mais? _________________________ 
8. Que tipo de material/equipamento tem disponível para a prática de exercício? 
_________________________________________________________________ 
9. A sua actividade física alterou-se durante o último ano? __________________ 
_________________________________________________________________ 
 
 
Estilo de Vida / Avaliação da Actividade Física  
Schneider, C.; Dennehy, C.; Carter, S. (2003) Exercise and Cancer Recovery. (Champaign, IL: Human 
Kinetics). Usado com permissão do MamaHelp  
Dieta  
1. Neste momento, está satisfeito(a) com o seu peso? _____________________ 
2. Qual o peso que gostaria de ter? ____________________________________ 
3. Em adulto, qual foi a sua pesagem mais alta? __________________________ 
4. Em adulto, qual foi a sua pesagem mais baixa? _________________________ 
5. Se já tentou perder peso, que métodos é que abordou? __________________ 
 
Registo de actividades diárias 
1. Tem dificuldade em realizar algumas das seguintes actividades? 
 
___ Carregar as compras ___ Rotinas de jardinagem 
___ Guardar compras / louça ___ Conduzir 
___ Lavar roupa / pôr roupa a secar ___ Fazer a cama 
___ Passar a roupa a ferro ___ Pegar nos filhos 
  
___ Outra _______________________________________________________ 
 
2. Responda se anteriormente assinalou alguma resposta,  
     a. A dificuldade que referiu começou a manifestar-se antes ou após o  
tratamento do cancro? ____________________________________________ 
     b. Se conhecida, descreva a causa de ter a respectiva dificuldade. _________ 
_______________________________________________________________ 
PORTUGUESE 
 
EORTC QLQ-C30 (version 3) 
 
Gostaríamos de conhecer alguns pormenores sobre si e a sua saúde. Responda você mesmo/a, por favor, a todas 
as perguntas fazendo um círculo à volta do número que melhor se aplica ao seu caso. Não há respostas certas 
nem erradas. A informação fornecida é estritamente confidencial. 
 
Escreva as iniciais do seu nome:   bbbb 
A data de nascimento (dia, mês, ano):   cececdde 
A data de hoje (dia, mês, ano):   31 cececdde 
  
  Não  Um Bastante Muito 
   pouco 
1. Custa-Ihe fazer esforços mais violentos, por exemplo,  
 carregar um saco de compras pesado ou uma mala? 1 2 3 4 
 
2. Custa-lhe percorrer uma grande distância a pé? 1 2 3 4 
 
3. Custa-lhe dar um pequeno passeio a pé, fora de casa? 1 2 3 4 
 
4. Precisa de ficar na cama ou numa cadeira durante o dia? 1 2 3 4 
 
5. Precisa que o/a ajudem a comer, a vestir-se,  
 a lavar-se ou a ir à casa de banho? 1 2 3 4 
 
 
Durante a última semana : Não  Um Bastante Muito 
   pouco 
6. Sentiu-se limitado/a no seu emprego ou no  
 desempenho das suas actividades diárias? 1 2 3 4 
 
7. Sentiu-se limitado/a na ocupação habitual dos seus  
 tempos livres ou noutras actividades de laser? 1 2 3 4 
 
8. Teve falta de ar? 1 2 3 4 
 
9. Teve dores?         1 2 3 4 
 
10. Precisou de descansar? 1 2 3 4 
 
11. Teve dificuldade em dormir?     1 2 3 4 
 
12. Sentiu-se fraco/a?    1 2 3 4 
 
13. Teve falta de apetite?    1 2 3 4 
 
14. Teve enjoos?             1 2 3 4 
 
15. Vomitou?          1 2 3 4 
 
 
 Por favor, passe à página seguinte 
 
PORTUGUESE 
 
 
Durante a última semana : Não  Um Bastante Muito 
   pouco 
 
16. Teve prisão de ventre?    1 2 3 4 
 
17. Teve diarreia? 1 2 3 4 
 
18. Sentiu-se cansado/a? 1 2 3 4 
 
19. As dores perturbaram as suas actividades diárias? 1 2 3 4 
 
20. Teve dificuldade em concentrar-se, por exemplo, 
 para ler o jornal ou ver televisão? 1 2 3 4 
 
21. Sentiu-se tenso/a? 1 2 3 4 
 
22. Teve preocupações? 1 2 3 4 
 
23. Sentiu-se irritável? 1 2 3 4 
 
24. Sentiu-se deprimido/a? 1 2 3 4 
 
25. Teve dificuldade em lembrar-se das coisas? 1 2 3 4 
 
26. O seu estado físico ou tratamento médico 
 interferiram na sua vida familiar? 1 2 3 4 
 
27. O seu estado físico ou tratamento médico         
 interferiram na sua actividade social? 1 2 3 4 
 
28. O seu estado físico ou tratamento médico         
 causaram-Ihe problemas de ordem financeira? 1 2 3 4 
 
Nas perguntas que se seguem faça um círculo à volta do número, entre 1 e 7, que 
melhor se aplica ao seu caso 
 
29. Como classificaria a sua saúde em geral durante a última semana? 
 
  1 2 3 4 5 6 7 
 
  Péssima      Óptima 
 
 
30. Como classificaria a sua qualidade de vida global durante a última semana? 
 
  1 2 3 4 5 6 7 
 
  Péssima      Óptima   
 
 
© Copyright 1995 EORTC Study Group on Quality of Life. Todos os direitos reservados.    Version 3.0. 
 EORTC  QLQ - BR23 
 
 
Às vezes os doentes relatam que tem os seguintes sintomas ou problemas. Por favor, indique em que 
medida sentiu estes sintomas ou problemas durante a semana passada. 
  
 
Durante a semana passada: Não Um  Bas-  Muito 
  pouco tante 
 
31. Sentiu secura na boca? 1 2 3 4 
 
32. A comida e a bebida souberam-lhe de forma diferente  
 da habitual? 1 2 3 4 
 
33. Os olhos doeram-lhe, picaram ou choraram? 1 2 3 4 
 
34. Caiu-lhe algum cabelo? 1 2 3 4 
 
35. Só responda a esta pergunta se teve quedas de cabelo: 
 Ficou preocupada com as quedas de cabelo? 1 2 3 4 
 
36. Sentiu-se doente ou indisposta? 1 2 3 4 
 
37. Teve afrontamentos? 1 2 3 4 
 
38. Teve dores de cabeça? 1 2 3 4 
 
39. Sentiu-se menos atraente fisicamente  
 devido à doença e ao tratamento ? 1 2 3 4 
 
40. Sentiu-se menos feminina por causa da 
 doença e do tratamento? 1 2 3 4 
 
41. Teve dificuldade em olhar para o seu corpo, nua? 1 2 3 4 
 
42. Sentiu-se pouco satisfeita com o seu corpo? 1 2 3 4 
 
43. Preocupou-se com o seu estado de saúde no futuro? 1 2 3 4 
 
 
  
Durante as últimas quatro semanas: Não Um  Bas-  Muito 
  pouco tante 
 
44. Até que ponto sentiu desejo sexual? 1 2 3 4 
 
45. Até que ponto esteve sexualmente activa?  
 (com ou sem relações sexuais) 1 2 3 4 
 
46. Só responda a esta pergunta se esteve sexualmente activa: 
 Até que ponto as relações sexuais deram lhe prazer? 1 2 3 4 
 
 
 
Por favor, passe para a página seguinte 
  
 
Durante a última semana: Não Um  Bas-  Muito 
  pouco tante 
 
47. Teve dores no braço ou no ombro? 1 2 3 4 
 
48. Teve o braço ou a mão inchados? 1 2 3 4 
 
49. Teve dificuldade em levantar o braço ou  
 fazer movimentos laterais com ele? 1 2 3 4 
 
50. Sentiu dores na área da mama afectada? 1 2 3 4 
 
51. A área da mama afectada inchou? 1 2 3 4 
 
52. Sentiu a área da mama afectada muito sensível?  1 2 3 4 
 
53. Teve problemas de pele na área ou à volta da área da mama  
 afectada? (por exemplo, comichão, pele seca, pele a escamar) 1 2 3 4 
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